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ABSTRACT 
Background: The medical histories of patients are data picked up by a doctor by 
making inquiries of the patient and of other individuals who know the individual and 
can give a reasonable response. In clinical trials, obtaining an accurate medical and 
treatment history is also an important factor in establishing whether or not a person is 
an eligible participant, and thereafter supports the assessment of any change in health 
during the trial, for example, the assessment of adverse events (AEs). 
 
Study objectives:  
To understand discrepancies between the medical histories from online self-reports, 
electronic medical records, and in-depth interviews of those applying to be part of an 
adult volunteer database for clinical trials; explore ways of engaging with potential 
volunteers, such that self-reported medical histories are as comprehensive as possible; 
explore the feasibility of accessing electronic records for those responding to 
advertisements. 
 
Methodology: This study was designed as mixed methods, with sequential 
explanatory design collecting quantitative and qualitative data and nested in an 
existing adult volunteer database. people from the Cape Town community were 
invited to join the database, in response to an advertisement and through a link to the 
database website; particularly those who were potentially eligible for a typical healthy 
volunteer trial, and who reported different information to that obtained from the 
electronic records. 
 
Results: 38 people responded to the online questionnaire, the majority being female. 
According to the online self-report questionnaire, ten people (10/38; 26.3%) had 
chronic medical conditions; mostly HIV (7/10; 70%). We accessed the Western Cape 
electronic medical records for only 8/38 (21%). Comparing the online questionnaire 
with the medical records, it was found that 25% of respondents had no difference in 
information. 10/38 people (26.3%) agreed to participate and were available for an in-
depth interview. 
The main findings were: 1) a very low response rate to the advertisement, 2) people in 
this community are willing to consider taking part in clinical research, but have 
different understandings of what that means, 3) there were discrepancies between 
online self-reported health and medication data and what was found in a pilot 
database of electronic public health records and during a face-to-face interview, 4) the 
reason for these differences, as perceived by participants, included forgetting some 
information, feeling it was not relevant or important to report because of the attributes 
of the online questionnaire and 5) these participants had no concerns about us 
accessing their electronic medical records. 
 
Conclusion: Our study provides some evidence for optimal places to advertise for an 
adult volunteer database, and the appropriate wording and format of both the 
advertisements and the online questionnaire. More efforts are needed to educate the 
general public on understand the meaning of clinical trials. Electronic medical records 
may be accessed to help understand potential participants’ eligibility for trials, but the 
feasibility of accessing such data timeously may need further negotiation. 
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CHAPTER 1: BACKGROUND 
 
Doctors collect medical histories of patients by interviewing the patient or 
individuals who know the patient. This information, combined with the results of 
physical examinations, tests and historical data in their medical records, may allow the 
doctor to make a diagnosis and propose a treatment plan(1,2) . With regard to clinical 
trials, obtaining an accurate medical and treatment history is also critical as it is the 
first step towards establishing whether or not a person is eligible for the trial. This 
baseline assessment is also essential for monitoring any change in health during a trial, 
such as the assessment of efficacy and safety, the latter through the collection of 
adverse events (AE) reports.  
Clinical trials may assess patients with an existing condition or healthy participants 
with no pre-existing conditions; both may provide valuable data, for example, on 
efficacy, safety, pharmacokinetics, and drug interactions. Potential participants’ prior 
medical and treatment histories are usually obtained from a combination of self-reports 
at the time of recruitment or screening and access to existing medical records, which 
are then assessed together with results from any trial-specific assessments(3) . 
Self-reporting is vulnerable to participants not accurately reporting their medical or 
medication history. This may occur for a variety of reasons, such as language barriers, 
the participant forgetting about a particular event or medication, their perceptions that 
some information is not relevant or important to report, or even because they are 
concerned, for various reasons, about disclosing certain information(3) . Meanwhile, 
obtaining complete medical records from all points of care accessed by a potential 
participant, which could be multiple healthcare providers and clinics, can be 
challenging for the clinical trial researcher. Healthy volunteer studies are especially 
vulnerable to poor record access and inaccurate self-reporting as they are often 
conducted in units that are separate from the patient’s routine medical care facilities. 
This is compounded when people obtain medical care from multiple healthcare 
providers, both public and private, or self-medicate(3,4). 
      In addition to undermining the validity of a trial’s results, inaccurate medical 
histories may contribute to participant being harmed if ineligible, applicants are 
enrolled, and there may be financial or ethical implications if the trial’s objectives are 
not achieved because the data is invalid(3,4) . 
To enable healthy volunteer studies, it is common practice for researchers to build 
a database of potential participants interested in taking part in future studies, such as 
the UCT Collaborating Centre for Optimising Antimalarial Therapy (CCOAT) 
database, produced in collaboration with the UCT Clinical Research Centre (see 
Appendix 1). This database is populated with demographic details and medical 
histories of members of the public who responded to advertisements and answered 
questions about their health and use of medicines, either telephonically or through an 
internet website. When a clinical trial in the planning phase, the database may then be 
queried and potentially suitable participants contacted to invite them to hear about the 
trial and undergo more intensive screening, based on the trial’s eligibility criteria. 
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Information technology is a rapidly expanding branch of science. In medicine, the 
increased availability of electronic medical records should enhance the researcher’s 
ability to build such a database of potential volunteers. Data obtained from available 
records and self-reports provide a comprehensive overview of a participant’s suitability 
for a trial. However, the feasibility of accessing such records for these purposes is 
unclear.  
This study, therefore, aims to understand whether and, if so, why self-reports from 
potential clinical trial participants are different to the data obtained from medical 
records using a pilot program that links information from multiple sources within the 
public healthcare sector in Cape Town, Western Cape. It also explores the feasibility 
of obtaining such electronic records, and the process of recruiting potentially healthy 
clinical trial volunteers. Together, these insights are expected to help refine the 
CCOAT volunteer database methods and contribute to cost-effective recruitment 
strategies for future clinical trials involving healthy volunteers.  
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CHAPTER 2: LITERATURE REVIEW 
 
2.1 The development of medicines 
Clinical trials are a fundamental aspect of the drug development process. The 
information collected from such trials may provide evidence that the product is 
effective and safe, which will support product registration and marketing(5) . This 
section will illustrate the steps that most drugs take from concept to the medicine 
cabinet. 
2.1.1 Drug discovery and pre-clinical research 
Researchers generally discover new drugs through insight into a disease process, 
which allows them to design a product to prevent or treat the effects of this disease. 
Discovery also includes observations regarding current treatments that have 
unanticipated effects. Promising molecular compounds need to be tested to identify 
those with useful effects and, initially, thousands of compounds may be potential 
candidates for development. Thus, the drug developer will first confirm which of these 
are associated with the disease in question and, after screening, will select hose that 
have demonstrable results(6,7) .  
Preclinical research takes many years to conclude results and, despite not being very 
large studies, they can provide important information on possible human dosing and 
toxicity levels.  In vitro testing examines the drug molecule within the laboratory, 
outside of a living organism, while in vivo testing observes its effects on animal models. 
By studying rodents or specific cells in a laboratory before testing a drug in humans, 
investigators aim to establish whether or not a candidate drug has the potential to cause 
serious side effects, such as cardiac, neurological, teratogenic or genetic toxicity. 
Animal studies, however, cannot fully elucidate how treatments would work in humans 
(7). 
Regulatory bodies, such as the United States Food and Drug Administration (US 
FDA), require pre-clinical researchers to use good laboratory practices (GLP), which 
establish the basic requirements for trials. These define accepted approaches to conduct 
such studies, appoint personnel, provide facilities, equipment, written protocols, 
operating procedures, study reports, and a system of quality assurance oversight to 
ensure the safety of products (6).  
As these tests are conducted, investigators will reduce the many drug molecules first 
identified to a small number of potential candidates safe enough to proceed to human 
clinical trials. 
2.1.2 Human clinical trials 
Once a promising compound is identified for clinical development, researchers 
conduct clinical trials, to collect information on its pharmacokinetics, 
pharmacodynamics, dosage, route of administration, the potential for adverse effects, 
and drug-drug interactions. Over time, they will examine the effects on different groups 
of people of varying ages, genders, race and ethnicity, and compare these effects with 
drugs for the same indication that are already on the market, if these are available. 
11 
 
Ultimately, researchers aim to establish whether or not the benefits of the new 
treatment outweigh the potential side effects(7) . 
As researchers design this clinical development plan, they will consider what they 
wish to accomplish for each of the phases, in order to answer specific research 
questions, leading to submission to a regulatory authority for the registration of the 
drug. Thus, each phase builds on the results from the preceding phase, helping to create 
a comprehensive understanding of the drug’s effects(5,8,9) :  
• Phase I trials: These are conducted in a small number of (usually healthy) 
volunteers with a focus on safety monitoring. The objective is to determine whether 
the drug is safe for human use, and to begin the process of understanding how the drug 
works in the human body .  
• Phase II trials: These are conducted in a larger sample of patients with the 
disease under investigation. The objective is to establish therapeutic efficacy and to 
further evaluate its safety. A significant objective of this phase is to determine the 
dosage for Phase III trials. If there is evidence of a disease-management effect and any 
associated risks are acceptable, the treatment may move to the next stage .  
• Phase III trials: These trials aim to confirm the efficacy of the drug and whether 
it is better than the current standard treatment(s). These trials are conducted in a larger 
population of patients who will have other medical conditions and might be taking 
additional medicines. This phase is also used to collect further information about the 
drug’s safety in the target population. These trials usually involve two groups: one 
group of patients will receive he standard drug, and the other group will be given the 
newer drug. They are typically blinded trials, in that the patients and the investigators 
are not aware of which treatment the patient is receiving. Due to the large size of the 
group of patients exposed to the therapy, this study provides a better understanding of 
any potential side effects of the new treatment . 
• Phase IV trials: After a drug or treatment has been approved by the appropriate 
government regulatory agencies, it is necessary to study its safety and effectiveness, 
how it works in reality in a larger number of people. Thousands of people usually 
participate in Phase IV trials . 
All trials will follow a specific plan, called the protocol, which is developed by the 
researcher or manufacturer. Beforehand, a team reviews what is already known about 
the drug from previous experiments in order to develop the trial’s research questions. 
This facilitates the creation of a comprehensive plan for the trial, which includes the 
objectives, design and methods, and the statistical analysis. The protocol will also 
include the type and number of participants, known as the sample size, their eligibility 
criteria, demographic data, the duration over which the therapy will be administered 
and endpoints that will be measured to achieve the objectives(10,11) .  
In addition to the different trial phases discussed above, clinical trials may either be 
interventional or observational. Interventional clinical trials involve giving a participant 
a treatment in accordance with a research plan. Observational clinical trials involve 
giving a participant a treatment in accordance with clinical practice. The appropriate 
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type of clinical research depends upon what is being studied and during which stage of 
development or beyond(12,13) . The following expands on these different types of 
studies:   
Treatment studies refer to an intervention, such as medication. 
Prevention studies explore more effective ways of preventing disorders from 
developing or recurring. Different kinds of prevention research may study medicines, 
vitamins, vaccines, minerals, or lifestyle changes. This may include the examination of 
exposure to substances and environmental factors that may raise or lower the risk of 
developing a disease or even reduce the risk of an accident. 
Diagnostic studies refer to the practice of searching for better ways of identifying 
a disorder or condition. Typically, they investigate the most effective methods of 
diagnosing disease. They may also be conducted to ascertain the safest, least invasive, 
and most cost-effective ways of determining if the disease is present. 
Screening studies determine the best means of detecting certain disorders or health 
conditions. They evaluate methods of detecting disease in the earlier, and possibly 
curable, stages of the disease to improve survival, for example, evaluating the effect of 
screening mammograms on breast cancer survival. 
The goal of genetic studies is to make efficient predictions about disorders by 
defining and understanding how genes and disease may be related to each other. By 
examining the genetic code of participants and their disease status, a study may expose 
routes in which a person’s genes make an individual more likely to develop a disorder. 
Epidemiological studies identify the manner, causes, and control of disorders in 
groups of people. These are useful for situating background rates of a condition, which 
can then be compared to what is found in clinical drug trials, for instance. 
Quality of life or supportive care studies look for ways to improve comfort and 
the quality of life for individuals with a chronic illness. Such studies estimate the 
potential of a medication, procedure, or non-medical intervention such as a support 
group, to lessen the symptoms of or those related to the treatment of a disease, for 
example, examining the effect of palliative care on the quality of life for people with 
cancer. Such studies may be effective in demonstrating that care improves quality of 
life and longevity . 
2.1.3 Regulatory review 
If a drug developer has evidence from preclinical research and clinical trials that 
proves the drug is safe and effective enough for its proposed use, they will apply to 
register the drug with various regulatory authorities. In the US, this will be the 
submission of a New Drug Application (NDA), from the start of clinical trials, to the 
FDA, culminating in the submission of a dossier of supporting evidence. Once the FDA 
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receives the submission, the review committee determines if it will accept the approval 
of the drug for registration. If accepted, the review team has six to ten months to decide 
on whether or not to approve the drug(14) . In South Africa, the equivalent body is the 
South African Health Products Regulatory Authority (SAHPRA), which is responsible 
for the regulation of health products proposed for human and animal use, the licensing 
of manufacturers, dealers and suppliers of medications, medical devices, radiation-
emitting devices and radioactive nuclides, and the conduct of clinical trials. Applicants 
must submit reports proving the quality, safety, and efficacy of such medications 
planned to be sold in South Africa. The South African regulatory review process is 
presented in Figure 1.  
 
Figure 1: Regulatory review process map for South Africa. Adopted from the 
Regulatory Review Process in South Africa: Challenges and Opportunities for a New 
Improved System(15) . 
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2.2 Clinical trial participation: the role of healthy volunteers and patients 
2.2.1 Background  
As indicated above, clinical trials are used to develop new medicines for the 
treatment or prevention of illness. They expand our understanding of basic scientific 
research and encourage an evidence-based approach to disease management(16) . 
Clinical trials may investigate new drugs, a combination of drugs, or a new approach 
to existing treatments. The outcomes of clinical trials can influence and improve patient 
care by providing information on the benefits and risks of new therapeutic, 
preventative, or diagnostic products. Clinical trials also contribute useful information 
about the benefits and safety of existing therapies, allowing doctors and patients to 
make informed choices about alternative approaches(17) . 
Clinical trials may be sponsored by pharmaceutical companies, medical technology 
companies, biotechnology companies, universities and other funding bodies, such as 
a government agency, for example, the National Institutes of Health(NIH), or the 
South African Medical Research Council(SAMRC)(17–19). 
During the conduct of a clinical trial, a sponsor is principally in charge of all the 
working aspects thereof. Their responsibilities include selecting capable investigators, 
providing them with the evidence needed to investigate accurately, and verifying 
appropriate monitoring of the trial, ensuring that the investigation is conducted in 
accordance with the general plan and protocols(20,21).  
The sponsor is also accountable for sufficient oversight of the manner in which the 
study is conducted, along with the explanation for and choice of monitoring systems. 
Any trial-related obligations moved to a contract research organization (CRO) must 
be in writing. As established in South African GCP, the sponsor will undertake 
quality assurance measures to ensure that all activities are in line with the monitoring 
plan. If a study is postponed or terminated early, a sponsor is obligated to inform the 
investigators, institutions, and SAHPRA, as well as update the South African National 
Clinical Trial Register (SANCTR). The sponsor then needs to preserve important 
documentation for at least 15 years, or for a minimum of two years subsequent to the 
final approval of a marketing application(22). 
A clinical trial is conducted by an investigator who is registered as a doctor or dentist 
and, depending on the population or protocol, performed in a clinic or hospital setting, 
or specialised research unit outside of a formal medical environment. Some clinical 
trials are “outpatient trials”, meaning that participants do not stay overnight. Others 
are “inpatient trials”, which means that participants will need to stay in the hospital or 
research centre for at least one night (5). Some trials (including Phase I trials) require 
healthy participants who have no previous medical conditions, while other studies 
apply inclusion criteria regarding the presence of certain diseases. Apart from Phase II 
and later trials, the latter would also be pertinent in Phase I for drugs that would be 
too dangerous for healthy volunteers, such as chemotherapy agents for cancer 
treatment(5,23) .   
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The investigator will work alongside a team of healthcare professionals, such as  
doctors, nurses, and pharmacists to conduct the various tasks involved . Investigators 
and sponsors alike must follow ethical and legal guidelines to protect participants’ 
safety. Ethics are especially pertinent as the philosophy behind a trial is to understand, 
not treat, and there will be remaining questions about the investigational drug needing 
to be answered. Trials should be designed, conducted and monitored in adherence to 
the same standards, whether they occur in South Africa, the United States  or elsewhere. 
By applying a scientific approach, important medicines are made accessible to people 
around the world through evidence-based healthcare(24,25) . 
The duration of trials varies widely and depends on what is being researched. 
During the informed consent process, participants will be provided with estimates 
regarding the duration of their participation. Some trials last days, while others 
continue for years. Before embarking on a trial, participants must know how long it is 
expected to last(5) . 
Participants may then be separated into different treatment groups. In a controlled 
trial, the trial group will be given the investigational treatment while the control group 
will receive 
an existing or standard treatment or placebo. The placebo is an inactive pill, liquid 
or powder that looks identical to the experimental treatment, but has no effect on the 
body. Participants are randomly assigned to either the control or non-control groups at 
the start of the trial. At the end of the trial, participants must be made aware of which 
group they belonged to. The results should be communicated to all participants so that 
they will be able to make future decisions about their well-being(5,6) . 
2.2.2 Motivations for participating in a clinical trial 
For many patients, clinical trials are an important step in accessing newly 
discovered therapies before they become widely available, and the choice to participate 
in one is personal and depends on each person’s unique situation. If a treatment proves 
successful, such participants may be among the first to benefit. In addition, they are 
closely monitored by healthcare providers during a trial and may emerge with a better 
understanding of their condition (5,26). 
As mentioned earlier other clinical trials rely on the recruitment of healthy volunteers, 
where there is no personal benefit to participation. People volunteer for such trials for 
a variety of reasons, including financial ones. This is especially true of people in lower-
income brackets, who might participate without being fully aware of the benefits and 
risks of the study. CROs in India have been known to use “middlemen” to recruit poor 
volunteers, who had no knowledge of what the studies were about and had not informed 
their families, mostly participating in the trials due to unsatisfactory income and 
unstable jobs(27). In developed countries, volunteers are often university students with 
a high level of education and reasonable living standards(28,29).  
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A study conducted in the US, Canada, and the Netherlands by Colfax et al. showed that 
most individuals provided altruistic motives for trial participation, having joined to 
assist with discovering an HIV vaccine and to support their community. Some had other 
motives, such as acquiring protection from the vaccine, being influenced to avoid 
dangerous behavior, receiving care or compensation, and also financial repayment(30). 
Such potential motivators have to be considered when recruiting for HIV vaccine trials 
in particular communities, regardless of context(31). 
A similar study in a Sub-Saharan location, namely Nairobi, Kenya, targeting volunteers 
for an HIV vaccine trial, showed that most participants had been inspired by potential 
personal and social benefits(32). The specific motivations for South Africans enrolling 
in medical trials are poorly understood as there are few studies available. However, 
research in South Africa has found that both adolescent and older volunteers in HIV 
vaccine trials were equally inspired by altruism, younger women were less likely to 
consider the trial remuneration and young men were more likely to perceive the trial as 
potentially providing protection against HIV(33). One Cape Town study also showed 
that obtaining medical care and contributing to scientific advancement seem to be two 
of the most frequent motivations for taking part in cardiovascular trials and that 
remuneration was less important. Understanding these findings will help improve 
recruitment strategies and enhance retention of subjects(34). There is a dearth of 
research relating to healthy volunteers in South Africa. However, a Portuguese study 
by Almeida et al. determined that participants with low education have been more likely 
to cite economic motivations for taking part in a trial(35), while a US study by Kass et 
al. discovered contrasting results: participants with greater education were more 
interested in monetary benefits than those with less education(36). 
Regardless of the target population, the interpersonal relationship between study 
participants and the recruiter has long been identified as integral to the recruitment 
process, although this has not been well studied(37–39). Some strategies integral to 
participant recruitment have been identified, such as regular follow-ups with 
prospective participants to inform them of the research study and building trust-based 
relationships between prospective participants and the researcher(3). Recruiter 
characteristics, such as enthusiasm and competency, positively influence the 
recruitment process(40).  Patel and colleagues further assert that qualities, such as 
conscientiousness, care, compassion, integrity, respect, tolerance, tact, and 
approachability, serve the researcher well in the recruitment process(41).  
One approach to recruiting participants is to assign a designated referral person who 
embodies the characteristics known to facilitate participant recruitment, this individual 
should conduct initial participant screening, identify eligible applicants, and inform 
them about the research study. A clear advantage of this approach is that a designated 
individual would be assigned specifically to participant recruitment. Barriers to this 
approach are the associated cost and the availability of specialized researchers 
dedicated to recruitment(42).  
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In a review of studies on recruitment, Treweek and his team aimed to quantify the 
effects of strategies for improving the recruitment of participants to randomised trials. 
They identified 68 eligible trials with more than 74,000 participants and all of the 
studies were in healthcare. They found 72 comparisons, but only three were supported 
by high-certainty evidence, and they also commented that only two were clearly 
effective. 
1. Telling people what they are receiving in the trial rather than not telling them 
improves recruitment. 
2. Telephoning people who do not respond to a postal invitation is also effective; 
although it is not certain if this works as successfully in all trials. 
3. Using a tailored, user-testing approach to develop participant information leaflets 
makes little or no difference to recruitment(43). 
 
2.2.3 Participants’ protection, rights, and informed consent 
Whether involving patients or healthy people, all clinical trials are designed to 
minimise the risks to participants, although some risk is unavoidable when the research 
involves new treatments, as there are still unknown potential effects. Mandatory ethical 
and regulatory reviews prior to the trial help to ensure that the aims, risks or benefits 
of a particular trial are thoroughly considered and that the chosen options are 
scientifically sound and ethically justified. 
Part of the ethical commitment of a trial is voluntary choice, while compliance with 
Good Clinical Practice (GCP) should signal to the public that the safety and rights of 
participants are protected(44) . It aims to:  
• protect the rights, safety, and welfare of participants 
• guarantee that data collected is reliable 
• have integrity and be of an appropriate quality 
• provide guidelines and standards for the conduct of clinical research 
 
The foundations of GCP were first laid out in 1947. The salient focus was that during 
any trial, researchers must guarantee voluntary participation, informed consent, and 
minimization of risk. Participants who choose to be part of the sample population are 
required to sign an informed consent form, before being enrolled in any study 
procedure. This is part of a process which ensures that a prospective participant in a 
clinical trial understands what known risks might be associated with the study and 
whether there are potential and unknown risks that may be associated with the chemical 
formulation or procedure under investigation (24,44).  
The participant should be given sufficient time to consider participation in the clinical 
trial and their questions addressed satisfactorily before agreeing to participate in the 
clinical trial. Signing the informed consent form and providing consent is not a 
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contract. Participants may choose to withdraw at any time from a clinical trial without 
any penalty, even if the clinical trial has not been completed (45,46).  Although 
provision is available for potential participants who are illiterate, the structure of 
informed consent is a written form, providing detailed information explained in 
accordance with GCP(42,44) .  
Table 1 - Summarised European Medicines Agency (EMA) guidelines for information 
to be provided to participants in clinical trials. 
Information provided to the potential 
participant: 
Participants must be informed: 
• Research involving the trial of 
drugs with possible random 
assignments  
• Aim and procedures to follow in 
the trial ( invasive and 
experimental aspects) 
• Reasonable risk and the relative 
expected benefit  
• Compensation or therapy in case 
of trial-related injuries 
• The anticipated expenses and 
remuneration 
• Responsibilities of the participant 
• Voluntary participation 
• The research team are granted direct 
access to the participant’s original 
medical records and these will be 
confidential and not publicly available 
• Participant’s identity remains confidential 
when results of the trial are published  
• Contact details of the research team to 
gain more information or in case of trial-
related injuries  
• Expected circumstances: participation in 
the trial may be terminated 
• Length of their participation in the trial 
 
For their part, participants agree to undergo the study procedures outlined in the 
informed consent form and follow the advice provided by the study team. It is 
important to ensure that the information is written clearly and concisely, and in the 
participants’ first languages(5,47). 
2.2.4 Eligibility criteria 
As mentioned previously, each clinical trial has a proposal or idea for the study, the 
conduct of which is described in detail in the protocol. Eligibility criteria define the 
patient population being studied, isolating the potential effects of an investigational 
drug. Enrolling participants with similar characteristics increase the possibility that the 
results will be an effect of the study variable and not an artefact of other factors. In this 
way, researchers may collect accurate and powerful results. Protocols, therefore, ensure 
that participants in a trial meet the same criteria, such as age, sex, and race, type of 
disease, current general health, and previous therapies. These criteria are also 
developed so that people are not exposed to undue risk.  
Eligibility criteria are separated into inclusion and exclusion factors: inclusion 
criteria allow a person to participate in a clinical trial and exclusion criteria prohibit a 
person from participating. These may specify certain factors, such as laboratory test 
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values, age, or other comorbid conditions that make a patient eligible or ineligible for 
enrolment.  
2.3 The practicalities and challenges of recruiting participants for clinical 
trials 
Before formal enrolment in a clinical trial, people who are interested in taking part 
will go through a screening process. Applicants who meet initial requirements are 
generally invited to a screening appointment where they will be provided with detailed 
information about the trial and, if they agree to participate, the informed consent form 
will be signed by both them and the person administering the information(48) .  
2.3.1 Advertising to recruit for clinical trials  
The methods used to promote specific clinical trials are usually controlled by 
legislation. In South Africa, an ethics committee must review the content of 
advertisements used to recruit participants for a study before they are used (49). The 
trial team may then look for potential participants via access points, such as patient 
organisations, hospitals, and pharmacies. Participants can also find out about clinical 
trials from online clinical trial registries, such as clinicaltrials.gov, the South African 
National Clinical Trials Registry (SANCTR), the Pan African Clinical Trials Registry 
(PACTR) or Center Watch (46). More recently, print-based advertising methods, such 
as posters in doctors’ offices, have been replaced by digital tools, including clinical 
trial recruitment websites and social media sites, for example, Facebook and 
Twitter(46,50) . 
While the methods used to enrol participants through advertisements can differ, all 
advertisements should display the contact information of the group conducting the 
clinical trial, details of the disease being studied, if relevant, and the aim of the trial. 
Ideally, eligibility criteria should also be provided, as well as a summary of reasons to 
be part of the trial, and the duration thereof. In contrast, advertisements must not 
promise any outcome, such as a cure for the disease, state that the drug being tested is 
safe or effective, or be coercive. This is especially important if a trial is recruiting 
vulnerable people, such as those with learning difficulties (50). 
 
Study sites in developing countries, in particular, need to develop an effective 
enrolment strategy, considering the necessities of the protocol and potential participant 
population. Options include hanging posters in clinic waiting rooms, offering 
brochures, writing letters to referring clinicians, placing advertisements in newspapers 
and, more recently, using the internet to attract interest. Each of these procedures has a 
possible role to play in the overall enrolment plan, although some might be more 
effective than others in a particular context. For instance, print advertising has proven 
to be a costly, but extremely effective, enrolment system compared to other means of 
enrolment. However, its success depends on the therapeutic area and the population of 
patients (51). 
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2.3.2 Overcoming challenges and strategies in the recruitment of participants 
Medical advances depend on patient participation in clinical trials. Unfortunately, 
meeting enrolment goals remains a challenge despite the money and effort invested(52) 
. Enrolment of participants in a study can be complex, frequently leading to the study 
being completed late, or even abandoned. This includes the fact that when there are too 
few volunteers, a conclusion may not be drawn, resulting in even promising treatments 
seeming to underachieve. The South African Clinical Research Association (SACRA) 
states that in 2008 approximately R2.2 billion was generated through clinical trials via 
international companies(53) . This business is affected by local regulatory approval 
times and the availability of appropriate research sites. However, international sponsors 
are interested in South Africa for research for various reasons, including the fact that 
the population is genetically and socio-economically varied(49) . Furthermore, South 
Africa has a strong regulatory framework and good telecommunications, with 
mandatory GCP training updated three times a year and is predominantly English-
speaking. Recently, in South Africa, several GCP courses have been presented and 
other clinical trial-related courses are slowly developing, for example, Introduction to 
Clinical Research and Project Management for Clinical Trials (53).  
Due to lack of capacity, building and transformation, the number of principal 
investigators (PIs) has declined by 11 % globally, with one suggestion being to 
encourage more young experts and professionals in various sectors to move from co-
investigator to PI(15) . Co-operation between stakeholders is essential, such as between 
SAHPRA and the National Health Research Ethics Council (NHREC). South Africa, 
as a participant of the African Vaccine Regulatory Forum  (AVAREF), in the meantime 
in 2006 which is pointed to improve the regulatory oversight of interventional CT have 
been behaviour in Africa. Bi-annual meetings with stakeholders started expanding to 
Ethics Committees and Academia. In addition, working on electronic systems to 
develop the timelines. Requirements for new innovative medications to struggle with 
the public health problem as well as diseases. and Source funding and creation of further 
study sites and facilities(22). 
Recruitment begins with the documentation and enrolment of participants. It includes 
providing adequate information to the potential volunteers to capture their attention for 
the planned research(54) . There are two main aims of enrolment. The first is to enrol 
a sample that sufficiently represents the target population(55) . The second is to enrol 
enough volunteers to achieve the sample size and power necessities of the research 
(56). 
Public perception is another factor that impacts recruitment. There is often a lack of 
awareness and many do not think they qualify to participate in the clinical trial. Fear 
and inconvenience are also contributing factors. There are a minority of patients who 
actively pursue participation in clinical trials. They are motivated to advance medical 
knowledge and assist in improving ways to avoid, detect, identify, control, and treat 
diseases (44,54).  
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Recruitment is enhanced when it comes as a recommendation from someone the patient 
trusts. When searching for trials, 60% of individuals go to their clinicians. The 
inspiration from physicians, pharmacists, family, friends, and others could affect the 
decision to take part. Compensation is not always a motivator, as not all clinical trials 
pay, but 78% of individuals reported that compensation had a significant influence on 
the decision to take part in studies. Some individuals participate in research to earn 
money, while payment is merely an advantage for others . Following a positive 
experience in a trial, 95% reported they would consider joining another one. This may 
explain the numerous applicants who take part in further studies after having gained 
more knowledge about research studies(40).  
 
Recruiting participants, both healthy and not, is an important and challenging task. It 
is also costly and can take more time than any other part of a study. Pharmaceutical 
sponsor companies lose up to $1.3 million per day in the US when a study postpones a 
drug’s development and registration. Up to 80% of clinical studies are not completed 
on time, and most studies are delayed by an average of six weeks. There is strong 
competition between pharmaceutical companies to produce the essential data as 
quickly as possible, and globalization of trials is motivated mainly by considerable cost 
savings, a large number of participants who could be quickly engaged in short timelines 
also to over control regulatory barriers in these developing countries which suggestion 
potentially lucrative markets.  
 
Furthermore, the mainstream of individuals has been engaged following recruiter-
completed questionnaires, highlighting the challenges encountered through exclusive 
recruitment approaches, training, and practical concerns for future studies, 
documentation from medical records and registers, or from ward and clinic-based 
plans, which enabled the accrual of a goal pattern of distinctly eligible participants. In 
addition, they reflect on the possibility of using cell phone and website tools. Numerous 
LMIC study strategies can be improved upon, and such deployment ought to lead to 
higher recruitment and retention success and quicker trial periods(57) . 
 
The effects of gatekeeping, which is when people or organisations assist in finding 
potential participants for clinical trials, have been insufficiently acknowledged in 
research although they may inspire interest and refer only those individuals who are 
highly likely to participate. This may result in “expert patients” with an above-average 
understanding of the disease being recruited for, instead of those with a more average 
clinical problem, or even more vulnerable participants, which could be a limitation 
needing to be acknowledged(58) . Moreover, there is a danger that a population 
becomes overburdened by research requirements, leading to reluctance to join future 
studies, thus negatively impacting future enrolment success(59) .  
Many factors that affect response rates for recruitment to clinical trials have been 
reported in literature: old age, male sex, non-white race, urban residence, low education 
status, unemployment or low occupational status, low family income, smoking, recent 
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illness or poor present health(56,60) . Understanding how this aligns with the 
recruitment plan and the desired sample is useful.  
Gender differences have also been demonstrated by the underrepresentation of male 
caregivers, such as male partners Purposive sampling could be a solution if this is 
recognized as essential to the integrity of the study(61,62). Finally,  consideration of 
the terminology used to describe a study can also affect participant enrolment(37) . 
2.3.3 Overcoming challenges through volunteer databases 
Efficiencies in recruitment for clinical trials may be achieved through web-based 
recruitment for specific trials and in setting up databases of potential participants, for 
future trials, whether for patients with a certain condition or healthy volunteers.  
Internet-based questionnaires can be an essential tool for collecting important self-
declared medical data to aid in the selection of participants for screening for a particular 
trial or for building up such databases. While not specific to trials, Kelstrup et al. 
suggest that the advantages associated with this approach to observational research 
include the minimum amount of infrastructure needed, lower cost when compared to 
individual recruitment and extraction of medical records, and the overall capability of 
involving many participants(63) . This web-based technique facilitates the rapid 
completion of enquiries, extracting a detailed medical history from the patient(63) . E-
recruitment is an informal term for any electronic-based recruiting and recruitment 
administration, such as recruitment marketing, which is a way to acquire research 
volunteers. In the United Kingdom (UK), there are several websites seeking healthy 
volunteers for clinical trials, such as UK Clinical Trials Gateway by the National 
Institute for Health Research (NIHR) or Clinical Trials Cambridge by 
GlaxoSmithKline GSK. People will search for relevant trials by choosing icons on web 
pages and filling in application forms, after which the research team will contact them. 
In South Africa, an example of this approach is the UCT Collaborating Centre for 
Optimising Antimalarial Therapy (CCOAT) database, in collaboration with the UCT 
Clinical Research Centre. 
2.4 Validity and accuracy of medical and medication histories in clinical trials  
For clinical trials, gathering an accurate treatment and medical history is essential 
to help establish if an individual is eligible for a given trial, and following that, to assess 
any change in health during the time of trial(2) .  
2.4.1 The factors that influence the accuracy of medical histories 
One challenge that is associated with self-reported medical history is the poor 
quality of data that may be generated. Data quality is dependent on the overall ability 
of a patient to recall their medical history, and their willingness to take part in research 
(63). Conformity between web-based self-report questionnaires and data generated 
from medical records has been studied in several medical conditions, mainly outside 
of the clinical trial environment. Such studies typically focus on the self-reporting of 
specific health conditions, including those that are associated with cancer screening. 
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In addition to affecting research, Vincent et al. (2005) state that in the US, 
incomplete medication histories, obtained during patient admission to hospital, are 
responsible for nearly 27% of all prescription errors. Valid medication histories during 
admission to hospital are essential elements of safety in the treatment outcome. An 
inaccurate medical history might result in inappropriate or interrupted drug therapy 
during and following the stay in hospital(64) . The current computerized order entry 
that is used by physicians could fail to properly identify the errors in reporting medical 
history. For example, the computer system might not detect omissions, such as 
medications that are taken prior to admission, without having a strong link to the 
pharmacy database within that community (63). 
Two main theoretical arguments have been applied when explaining the sources of 
validity problems associated with self-reported data on medical histories. These are 
known as the situational and cognitive perspectives(63) . Cognitive perspectives tend 
to focus strictly on the general mental processes that act to underline self-reported data 
and tend to attribute problems of validity to the type of inaccuracies that arise from 
recall, comprehension, and other cognitive operations. In contrast, the situational 
perspective tends to focus on problems of validity that are associated with the 
conditions during the interview, as well as perceptions of social desirability. It is 
important to note that the two perspectives are not mutually exclusive. For instance, 
basic cognitive arguments have been expounded on in trying to account for the known 
situational factors (65). 
Brener, Billy & Grady further postulate that four main cognitive processes impact 
question answering: retrieval, comprehension, decision-making, and generation of a 
response. Respondents tend to first engage themselves in a comprehension process that 
determines how a given question is interpreted and encoded within the memory. The 
known retrieval cues are then generated on the mere fact of output from the whole 
process and then applied in searching for memory in the subsequent stages of retrieval. 
The overall sufficiency of the information retrieved is then evaluated in the process of 
decision-making. If the information retrieved is assumed to be relevant to the question, 
then the respondent will give a response. If they deem the information inadequate, then 
they will make additional retrieval attempts or initiate heuristics. Scholars propose that 
errors tend to arise during all of these stages, which subsequently leads to the problem 
of the validity of medical history data. In addition, the specific cognitive operations 
applied when responding to a question can differ based on the period of time being 
referenced and the specific response needed. For instance, regarding the frequency of 
a given behaviour, validity varies greatly between questions(65) . 
Further studies have also shown that the context of a question, together with the 
environment in which one is administering the question, also has an impact on how 
different cognitive processes tend to be executed. The process can eventually result in 
systematic biases when responding to the questions. 
Brener, Billy & Grady use a situational perspective to explain the factors influencing 
the validity of medical and medication histories obtained from potential healthy adult 
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clinical trial participants. The situational perspective, in this case, focuses specifically 
on the validity problems that arise from the condition of the external environment 
rather than internal processing. Factors that are hypothesized to influence validity 
comprise of the availability of other people when participants are being asked questions 
about their medical history and their perception of the level of confidentiality or 
privacy that their responses are afforded(65). Social desirability, described as having a 
desire to give someone a favourable impression of oneself, is another construct that 
causes situational biases and hence, invalid self-reported medical histories(66) .  
Questions influenced by social desirability bias might have response options that match 
desirable attributes or activities that are considered desirable to be part of. Literature 
reports that another construct associated with social desirability bias is the desire to 
seek attention. This attribute is most likely to lead to response biases among adolescent 
groups, for whom some behaviours such as drug use, alcohol abuse, and even sexual 
behaviours, are closely linked with status in several settings. 
Brener, Billy & Grady  suggest that a perceived lack of privacy, anonymity, or 
confidentiality in the situational context in which these questions are being asked can 
result in response biases due to fear of reproach. For instance, behaviours that are 
considered to be stigmatized, illegal, or laden with heavy moral implications are at 
greater risk of inaccurate reporting(65) . 
Vincent et al. argue that, based on similar situational context pressures, the patient’s 
self-reported medical history might be concordant with the information contained in 
medical records. They affirm that close to 90% of self-reported medical histories for 
hospitalization are concordant. Concordance has been reported to vary from as low as 
80% for infections to nearly 100% for fractures or injuries, and other medical 
conditions. These arguments by Vincent et al. concur with other studies that have 
investigated concordance of self-reported medical history with the existing medical 
records(64) . 
Kim et al. compared self-reports and medical records in relation to examinations of the 
eye and diabetes-related conditions, and found differences in the various levels of 
assessment of the health status of the participants. These figures confirmed that self-
reported assessment is not associated with highly specific evaluations of the health 
status of a participant. It was also reported that sensitivity regarding outpatient visits 
and general hospitalization was very high among those people who self-reported their 
medical history to be poor than among those who reported their history as good. 
Specificity was reported to be higher among the participants who self-reported their 
health to be useful compared to those who reported their health to be poor (Kim et al., 
. Participants with sadness, depression or those who had not received the necessary 
medical services were found to be most likely to provide a false medical history 
compared to the opposite group(66) . 
Kelstrup, Juillerat & Korzenik  investigated how patients with inflammatory bowel 
disease (IBD) self-reported their previous diagnosis. The researchers, in this case, 
25 
 
compared the chart reviews, made available by the healthcare providers, and the self-
reported diagnosis history of the patients. The information within the hospital database 
was more accurate, with a specificity of around 90% for the diseases investigated and 
sensitivity of 88%. The study noted that self-reporting was only 69% accurate among 
patients. These findings are very much consistent with the arguments put forward by 
Eze-Nliam et al. , who argued that 30% of their patients provided inaccurate medical 
histories regarding the diagnosis of IBD (63,67). 
Patients’ medical records have an essential role in clinical trials, particularly as they 
will hold key data to inform investigators of their eligibility for trial participation, 
including those volunteering for trials as healthy volunteers. Conversely, it is vital to 
ensure that a current record of the medical history of trial participants is available to 
any treating physician (i.e. outside of the trial team), during and after the trial, as all 
data relevant to the study will be filed in the medical records, thus they come to 
represent the source material of the clinical study. They are used to provide 
corroborating information to the sponsor, and they should be available for inspection 
by regulatory authorities (4,68,69) . 
Access to electronic medical records may, therefore, improve trial quality, as shown in 
retrospective studies, although there is little literature on this topic(68–70) . More needs 
to be done to ensure that the self-reported medical histories of potential adult volunteers 
in clinical trials are as comprehensive as possible(67) .  
2.5 Opportunities for accessing electronic records to aid clinical trial conduct 
The Provincial Health Data Centre (PHDC) has developed a pilot database that links 
data from the following five resources: 
• Electronic registers of human immunodeficiency virus (HIV) and tuberculosis 
(TB) treatment initiation and regimens. A three-tier approach permits the South 
African Ministry of Health (MoH) to strategically perform one of the tiers in 
every facility with antiretroviral therapy (ART) facilities. Every tier product the 
similar nationally essential monthly registration and three-monthly statements 
so that productions from the three tiers could be combined into one data at the 
level of the health system(71)  (Figure 2). 
• Hospital and primary healthcare patient registration and admission systems; 
outpatient and primary care clinic visits 
• Hospital and primary care birth registers 
• Various laboratory databases 
• Dispensing data from a centralised dispensing system and warehouse pharmacy 
While intended to help clinicians with patient management, this data-linkage system 
could be a beneficial resource for clinical trial investigators to access available medical 
records of the people who apply to take part in clinical trials and help ensure their 
eligibility and safety during a trial. 
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Figure 2: The three-tier monitoring and evaluation system for ART. Adapted from the 
National Department of Health in December 2010(71). 
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Chapter 3: Methodology and Data Analysis 
3.1 Rationale of the study 
This study aimed to investigate optimal methods for obtaining medical histories for 
future healthy volunteer trials by inviting members of the public to join a volunteer 
database via an online questionnaire portal and asking them for permission to access 
available electronic medical records.  
3.2 Study methodology 
3.2.1 Study objectives 
• To understand discrepancies between medical histories obtained through online 
self-reports in response to a questionnaire, available electronic medical records in the 
public healthcare sector, and the information obtained during in-depth interviews with 
members of the public applying to join an adult volunteer database for clinical trials. 
• To explore ways of engaging with potential adult volunteers in clinical trials, so 
that their self-reported medical histories are as comprehensive as possible. 
• To explore the feasibility of accessing available electronic records for potential 
adult volunteers in clinical trials, responding to advertisements It was a mixed methods 
study with sequential explanatory design collecting quantitative and qualitative data. 
3.2.2 Study design and participants 
This study was designed using a mixed-methods  approach, with sequential 
explanatory design collecting quantitative and qualitative data, and was nested in an 
existing adult volunteer database (Appendix 1). People from the Cape Town 
community were invited to join the database in response to advertisements that 
provided a link to the database website (Appendix 2). On the website, they completed 
a brief medical history according to a pre-defined questionnaire (Appendix 3 ) and 
could indicate consent for the study team to access their available electronic medical 
records or the reason for non-consent to access records if this was volunteered.  
A subset of those potentially eligible for a typical healthy volunteer trial, who 
reported different information to that obtained through the electronic records, were 
invited to attend a face-to-face appointment, where consent was requested for a simple 
physical examination and in-depth interview (Topic guide, Appendix 4). If no such 
volunteers were identified, a random sample was chosen from those who responded to 
the advertisement, and they were invited to the face-to-face appointment. 
Advertisements and the online questionnaire were restricted to English for financial 
reasons, and only those who were fluent enough in English to converse with the 
interviewers, as ascertained during phone calls when making appointments for the 
interview, were invited. Advertising posters From July 2018, advertising posters were 
placed at various locations within Groote Schuur Hospital in Cape Town, to recruit 
visitors rather than patients. Additionally, web banners were placed online in October 
2018 and February 2019. Printed advertisements appeared in Vukani newspaper. 
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3.2.3 Data collection and management 
Quantitative 
Quantitative data included the number of participants responding to the 
advertisements, completing the online questionnaire, consenting or not consenting to 
access to electronic medical records and the interview, the number, and nature of 
medical history items obtained from the questionnaire, the database review and the 
interview. We also recorded basic demographic data, such as age, gender, home 
language, and employment status, and the results of the physical assessment, including 
temperature, heart rate, blood pressure, and body mass index (Appendix 3). 
Qualitative 
Using a topic guide (Appendix 4) in the recorded interview, participants were asked 
questions about where they had seen the advertisement, and their perceptions of it, their 
understanding of clinical research and trials, and their medical history, including any 
treatments used in the previous four weeks. Thereafter, the interviewer asked for the 
participants’ assistance in improving methods of obtaining accurate medical and 
treatment histories regarding the online questionnaire, the electronic medical record (if 
available), and the physical examination and notes taken during the interview. This 
included exploring their understanding of the reasons for and process of obtaining their 
medical history information; the reasons for reporting or not reporting information 
obtained through the questionnaire, database review and interview; and the 
participant’s advice on how clinical trial teams may collect comprehensive and 
accurate data during the process of building a volunteer database, with reference to 
advertisements and the website portal. We also explored how potential participants felt 
about us accessing their electronic medical records. 
Recordings were transcribed according to a standard operating procedure (SOP) and 
transcripts were then imported into folders in NVivo® 12,a qualitative data 
management software program, which was restricted to the Master of Philosophy 
student and primary supervisor. 
3.2.4 Sample size and analyses 
There were no sample size calculation as enough potential participants who 
completed the online database questionnaire were invited for interviews until there was 
a saturation of themes being obtained in the qualitative analysis in excel spread sheet 
by frequencies. However, a maximum of 20 interviews were anticipated. 
Quantitative data, including demographic variables, medical histories and 
medications used were described by number and proportion. Transcripts were analysed 
thematically, including descriptions given for differential reporting by question 
method; relevant text was examined line by line for repeating ideas, and the underlying 
meaning or concepts behind statements (72,73). These initial codes were entered into 
the NVivo® program and themes were identified as more transcripts were coded. The 
MPhil student conducted the initial coding, which was reviewed by the primary 
supervisor and an initial coding template was then agreed on. Thereafter, the MPhil 
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student proceeded with coding the remainder of the transcripts, which was again 
examined by the supervisor, and any changes to the coding were discussed. Once 
coding was complete, the data were explored for theoretical constructs(72,74) . 
3.2.5 Data handling and record-keeping 
At the outset of this study, we created secure electronic and paper-based filing 
systems to keep all study-specific information as per the CCOAT adult volunteer 
database protocol for the online information, supplemented by secure storage for the 
qualitative and physical examination data obtained in the interviews. 
 3.2.6 Ethical considerations 
The study protocol was approved by the University of Cape Town Human Research 
Ethics Committee and is considered a low risk for participants (Appendix 6). Any 
personal data was protected, and no identifying features will be revealed in subsequent 
publications. Consent for the completion of preliminary demographic and health details 
in the online questionnaire was integral to the platform, while written information and 
consent documents were used before the face-to-face interview (Appendix 4 and 5). 
Potential participants were requested to allow access to their available electronic 
medical records and the information was not obtained if no such permission was 
provided.  
Before the in-depth interview, the investigator read through the form with each 
participant and offered them the time and opportunity to enquire about the details of 
the study and to consider taking part. Participants were made aware that the interview 
would be recorded and that they were not required to discuss details if they were not 
comfortable doing so plans were in place for illiterate participants, such that an 
independent witness would have been used to validate that the verbal information was 
an accurate reflection of the written form. 
If a participant was eligible for a face-to-face meeting, they were offered R75.00, 
as compensation for travel expenses and inconvenience, to attend the appointment as 
per the existing database protocol. All participants were also offered refreshments 
during the interviews. 
Registered participants can request to be removed from the database at any time, for 
any reason (or no reason) upon their request. 
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Chapter 4: Results and Discussion 
4.1 Results 
Between July 2018 and October 2018, we received 11 responses, and between 
November 2018 and February 2019 there were a further 13. The last advertisement in 
February 2019 elicited 14 more responses. Therefore, in total, the three advertising 
campaigns over eight months resulted in 38 respondents. 
Study participants 
Table 2 provides a summary of the demographic characteristics of the 38 people who 
responded to the online questionnaire. The majority of respondents were female (28/38; 
73.6%) with median age, at the time of the survey, of 31.4 years (19-42 years), and 
median height and weight of 160 cm and 77 kg respectively. 22/38 (57.8%) reported 
that they spoke or read English, 15/38 (39.4%) spoke Xhosa and 1/38 (2.6%) spoke 
Tswana. All participants gave consent for us to access their medical records from the 
PHDC except for 2/38 (5.2%), and a further 3/38 (7.89%) refused to give consent to 
remain in the database for consideration for future clinical trials. 
    Table 2: Demographic data of study participants 
Total 
numbers 
Gender 
Female % 
Median 
Age Ys 
Median 
Height Cm 
Median 
Weight 
Kg 
English 
speaker 
%  
Previous 
clinical 
trials % 
38 73.6 31.4 160 77 57.8 5.2 
 
Medical and medication histories 
Table 2 provides a summary of past medical, surgical and medication histories from 
three methods: online self-report questionnaire, online medical records, and an in-depth 
interview. According to the online self-report questionnaire, ten people (10/38; 26.3%) 
had chronic medical conditions, the majority being HIV (7/10; 70%). One of these had 
multiple comorbid conditions: previous pulmonary tuberculosis, systemic 
hypertension, chronic kidney disease, and arthritis. One (10 %) had Crohn’s disease, 
one had sinusitis and one had polycystic ovary syndrome and endometriosis. No 
participants were reportedly suffering from diabetes, epilepsy, asthma, or heart 
problems. Twelve participants (31.5%) had had previous surgery, seven being 
caesarean sections, two had undergone an appendectomy, one a keloid removal, one a 
dental procedure and one a minor facial operation. Nine (23.6%) were on chronic 
medication, the majority of these (7%) being HIV antiretroviral therapy (ART). One 
was also reportedly taking an iron supplement and medication for a kidney problem. 
One was on azathioprine for Crohn’s disease and another on combined oral 
contraceptive pills. There were 10/38 (26.3%) who reported being active smokers, with 
a median smoking index of three cigarettes per day. 11/38 (28.9%) were social alcohol 
drinkers and 2/38 (5.2%) were recreational drug users, one of which used marijuana 
and another used cannabis oil. All respondents had recently visited day clinics for 
different reasons, the majority for flu (14/38; 36.8%), a general check-up (8/38; 21%) 
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and a pregnancy follow-up (5/38; 13.1%). A minority had visited such a facility for the 
treatment of a rash, a dental problem, and constipation. 
We accessed the Western Cape electronic medical records for only 8/38 (21%). This 
was largely due to a delay in obtaining permission from the data centre. The protocol 
was first submitted on 6 August 2018, to which they responded on 30 August 2018, 
asking for the study ethics approval form, which was then sent.  Feedback on 18 
October 2018 was in the form of a request for a protocol amendment to amend the 
wording on the online questionnaire to specify that the interviews would be exploring 
differences between the online questionnaire responses and electronic records. The 
revised protocol and re-approval from the ethics committee was submitted on 8 
November 2018, after which we received approval on 25 January 2019. We obtained 
the first dataset of participants on 15 February 2019, and a second list on 5 March 2019. 
As of now, no further data has been received. Unfortunately, these unanticipated delays 
precluded us from accessing data for the first 24 questionnaire respondents.  
Comparing findings from the online questionnaire and the medical records, it was 
found that 25% had no difference in information. The remaining 75% had 
discrepancies, as summarized in Table 2. 10/38 people (26.3%), the majority of whom 
were female (6/10; 60%), agreed to and were available for a face-to-face, in-depth 
interview. Unfortunately, we did not have access to their medical records (Table 3). 
The vital signs of those interviewed demonstrated a median blood pressure of 120/65 
mmHg, a median pulse of 82.5 beats per minute and a median temperature of 36.95˚C. 
The median body mass index of those interviewed was 28 kg/m2. 
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Table 3: Discrepancies between the online survey and medical records 
 
 
 
 
 
 
Respondent 
number 
Gender Online survey Medical records 
PMHx PSHx Medicatio
ns 
PMHx PSHx Medications  
1.  Female None None None  None  Dental 
Procedure 
Clotrimazole, 
Flucloxacillin, 
Paracetamol 
2.  Female HPT, TB, 
HIV,  
Arthritis, 
Kidneys 
problem 
C/S Iron 
tablets, 
ARVs 
Atopic 
Dermatitis 
None  TB treatment, Pyridoxine, 
Promethazine, 
Hydrochlorothiazide, 
Aspirin, Valproic acid, 
Tramadol, Paracetamol, 
Laxative, Trimethoprim, 
Enalapril, Amlodipine 
3.  Female HIV None None HIV,  
Chronic 
Constipation 
None Sennakot, Liquid paraffin, 
Ibuprofen, lidocaine, 
Amoxicillin 
4.  Female None None None None None None  
5.  Female None None None Dental 
problem 
None Metronidazole, Sodium 
citrate, Azithromycin 
6.  Female None None None Dental 
problem 
None None 
7.  Female None  None  None  Family 
planning  
  
8.  Male None None None None None None  
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Table 4: Discrepancies between the online survey and face-to-face interview 
 
ART =antiretroviral therapy, HIV= human immune deficiency virus, C/S=caesarean section, PMHx= past medical history, PSHx=past surgical history, COC=combined oral contraceptive, 
CD=Crohn’s disease, AZA=azathioprine, PCOS=polycystic ovary syndrome, TB=Tuberculosis, Vit =vitamin, None= no past medical, surgical and medication histories, ND=no discrepancies. 
Respondent 
number 
Interview 
ID 
Gender Online survey Interview 
PMH
x 
PSHx Medicatio
ns  
PMHx PSHx Medications  
1.  ID6 Female None C/S Cannabis 
Oil 
None None Hair growth tablets, 
Sleeping pills, 
Vitamins 
2.  ID2 Female None None None TB Breast 
cystectomy  
None  
3.  ID10     Male CD None AZA Smoker 
Alcohol 
user 
None  Vit B12 injection, 
Vit D, Calcium 
4.  ID1 Male None  Minor 
fascial 
surgery 
Marijuana Severe 
burn, 
Chronic 
sinusitis 
None  Diclofenac 
5.  ID9 Female None C/S None None None  COC 
6.  ID8 Female HIV None ARVs Shingles None  COC, Marijuana 
7.  ID4 Female None None None ND ND ND 
8.  ID3 Male None None None ND ND ND 
9.  ID5 Male None None None  Alcohol 
user  
 Vit B complex, 
Paracetamol, 
Acetylsalicylic acid 
10.  ID7 Female HIV None ARVs None None Antacid  
Qualitative data  
The qualitative data explored participants’ understanding of clinical trials and research 
studies, the reasons for and process of obtaining their medical history information, the 
participants’ advice on how clinical trial teams may collect comprehensive and accurate data 
during the process of building a volunteer database, with reference to advertisements and the 
website portal, and the reasons for reporting or not reporting information obtained through the 
database review and interview. The main themes are described below. 
Different understandings of clinical trials and research studies 
The concept of a clinical trial had different meanings for the respondents, with two 
participants having a very accurate understanding, two appeared to have no understanding or 
an incorrect understanding, and also found it difficult to explain what they did understand, and 
the remaining eight were on a continuum of good to poor understanding. When asked why 
some members of the public had difficulty understanding the advertisement, one of the 
participants, with a good understanding, explained it as follows: 
“Clinical research is not something that the general public consider, people in 
universities do.” [ID 1]  
Although difficult to elucidate explicitly, the participants with a very poor understanding 
most likely believed they were applying for a job and were being recruited to be part of the 
research team, even if it was in a voluntary role.  
“INTERVIEWER: So, in terms of clinical research studies, what do you think your 
role would be…? 
INTERVIEWEE: …. to take the service to the people who [can’t] afford [to] go to 
the clinics or something like that.” Later: “Maybe they are old people who don’t 
know how to go to the clinics…” [ID 9] 
Of those with a very good understanding of the rationale, one participant gave a near-perfect 
description of the rationale and process, summing up her involvement as, 
“You’re looking for healthy people that’s willing to volunteer and take part in 
research” and “[You will] check if I’m actually eligible, if I meet the criteria that 
you’re looking for, of taking medication, you’ll obviously monitor me, maybe do 
some tests and check what the outcome was.” … “Technically my role would be the 
rat.” [ID 6] 
Despite the advertisement specifying that we were seeking healthy volunteers for a 
potential trial that would not treat their condition, some indicated that they did, in fact, believe 
the research would do so one of these was someone living with HIV on antiretroviral (ARV) 
medication, while another was living with Crohn’s disease.  
Healthy living with a chronic condition 
In both of the above-mentioned cases, the participants considered themselves to be healthy. 
The participant with Crohn’s disease, who had a good understanding of the process of clinical 
research, could not explain why he had applied when the advertisement explicitly stated that: 
“To qualify, you need to be/have: NO stomach or bowel problems”.                                                                                  
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“INTERVIEWER: So, we do say here “no stomach or bowel problems”, do you 
remember seeing that part? 
INTERVIEWEE: I can’t remember. 
INTERVIEWER: …It says here “healthy volunteers”. Do you consider yourself in 
this group? 
INTERVIEWEE: I would like to say so.” [ID10] 
    Helping others, through working in, or taking part in clinical research 
 
Although some participants did not fully comprehend the concept of clinical trial 
participation after this was explained to them, of those who did understand, most were 
interested in taking part. They largely felt that participation would potentially help others, 
although some understood that it may help them, which, as previously discussed, represented 
a misunderstanding of the concept of being a healthy volunteer. They indicated that we needed 
healthy volunteers, but did not have many, hence the use of advertising to set up a database so 
that we could come back to them for future studies. 
 
“What I saw was… You need volunteers to do the research. Probably didn’t have 
a lot of volunteers. It’s probably a difficult thing to advertise and get in front of 
people’s faces. It’s the first thing I found and obviously I saw I qualified for all the 
criteria: not pregnant.” [ID 1]  
 
Willingness to accept taking an experimental medication 
 
Most would accept trying a new experimental medication, even if they may experience 
adverse effects, as they trusted that the doctor (i.e. the investigator) would not give them the 
incorrect medicine and make them sick. The participants who had pre-existing conditions were 
concerned that the new medication may lead to a worsening of their condition. Considering 
the unknown side effects, they also thought that every person would have different reactions, 
but were pleased to be trying the new drug and would just be very careful. 
 
“INTERVIEWEE: If I take a new medicine, maybe it’s going to get a side effects 
or something like that. 
INTERVIEWER: And what do you think about that? 
INTERVIEWEE: But I trust you don’t let me – you [won’t] give me the wrong 
medicine.” [ID 9] 
 
 
The practicalities of taking part in research may be a barrier 
       At the same time, it was found that some participants may base their decision to join a 
study to receive payment, but may then decline involvement because their family would not be 
supportive or they could not take time off from work, although this might be possible if the 
study doctor could provide a sick note for their employer. 
 
“I don’t have any problems with [taking part in a trial]. The only thing is that it mustn’t 
clash with my work.” [ID10] 
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Improvements to the content and placement of advert to maximize recruitment     
A number of participants felt that the advertisement was placed in an appropriate location, 
although some suggested we advertise more widely. For instance, posters could be placed in 
clinic waiting rooms, particularly family planning clinics where people were likely to be 
healthy, in local shops or shopping centres, libraries, community centres, and sports facilities, 
particularly soccer stadiums. One person was suggested the MyCiTi bus network as an 
appropriate place for a poster. Another was pleased to see the advertisement on the clinic wall 
where she was accompanying a sick relative and had taken a photo of it to complete online. 
 
 “….some people who go to clinics, they are healthy but maybe they are going for some 
other things.”[ID 5] 
 
Suggested online locations included social media platforms, such as Facebook (which could 
raise awareness of clinical trials, including what taking part in a clinical trial involves) and 
Gumtree, in addition to the online newspapers that had been used, as people are becoming 
more proficient in their use of the internet. One person suggested the job site, 
https://www.indeed.co.za/, as it advertises both paid and unpaid opportunities. 
 
While they generally approved of the advertisement itself, respondents suggested it would 
have been advantageous to have a larger poster, or possibly even a leaflet, in colour and with 
pictures. The link to the questionnaire could have been improved with a direct link to 
information about clinical trial participation. It was also felt that it is important to use a large 
font and simple language, as well as highlight the benefits and reasons for participating in 
research.  
 
“INTERVIEWEE: You know it is already very basic. It is very – yes, but basic for you guys 
may not be basic for someone outside.” [ID 10] 
 
“INTERVIEWEE: To the whole picture of what it is that you’ll be doing. Maybe for more 
info click on this link and then have an FAQ type.”[ID 1] 
 
Improvements to the online questionnaire 
Although there was agreement that the questionnaire was generally clear, some participants 
did suggest recommendations for improving it, to prevent misunderstandings about the 
requirements of the trial. 
This included changing some words, such as “before, rather than past”, guiding respondents 
through examples for some questions (e.g. the mention of “marijuana” specifically), and 
giving a better indication of the time frame for certain required information. 
 
Additionally, participants suggested that asking about a quantity of alcohol is difficult because 
“one glass could be whisky”, and they mused how best to ask this question. Regarding 
smoking, some suggested it would be preferable to ask, “When last did you smoke?”  
 
 “INTERVIEWEE: Maybe also if it’s a ‘do you drink alcohol?’ and then maybe also ‘when 
last have you had?’ and then per week……….Like for me, I don’t drink every week……Maybe 
the per week would maybe need to change. I am thinking if you ask when last you have drunk 
and then how much do you drink on an occasion. I’m just trying to figure out how much a 
person drinks when they drink.”[ID 10] 
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Talking about health in the interview was a useful way to be comprehensive 
 
Some participants reported that the conversations with the researcher in the in-depth 
interview enabled them to gather additional information about their health and use of 
medicines, including details they did not mention in the online questionnaire. The reason for 
this was that, by the end of the conversation, the researcher had a more comprehensive 
understanding of the participants’ health than from the online form, which people sometimes 
failed to fill in completely. 
 
 “INTERVIEWEE: I think the interview is probably the best way (to get comprehensive 
information on medical history)…….this kind of interview where you can directly ask 
questions like you would ask ‘do you recall from an injury perspective?’ So, if somebody filled 
out the form, I think most people would have the same sort of thing that I had, in terms of oh, 
I’m going to take part in a study. Do you have a condition? No. I fill out medical aid forms. I 
just had to fill out, because I’m moving medical aids now and similar sort of questions I also 
answer now, because it’s not something that affects my risk pattern or anything like that. It’s 
a once-off.” [ID 1] 
 
“INTERVIEWER: Yes okay. So what sort of helps you remember some things about your 
health and treatments than others? 
 
INTERVIEWEE: I think just – I was speaking to you now, it’s sparking things. Yes. Maybe 
at the time, I [did] the questionnaire a bit in a hurry. Maybe I thought that like saying [I was 
only] on Azathioprine and not the other medication.” [ID 10] 
 
Reasons for reporting or not reporting information  
 
When discussing discrepancies between what they said in the questionnaire and the face-
to-face interview, participants often said they “forgot to report things”, or “were in rush”, as 
mentioned above. 
It did not seem relevant: participants did not mention anything unrelated to the research, 
and, therefore, it was not necessary to report, did not take it for specific diseases, or even 
consider it a medication, as that was for when one was ill. 
“INTERVIEWEE: I didn’t think [the sleeping tablets] would count because I was thinking 
more like [medication] if you’re ill, you know so I’m not taking it for any illness, I’m just 
taking it.”[ID 6] 
Similarly, some information was perceived as not what was being asked for, or the 
medication was only used intermittently. If it was not current, frequent, or persistent use of 
medication, they did not feel the need to report it. 
 “INTERVIEWEE: No, the problem is that I think it’s just the B-co. and the Panadol like 
it’s not the medication that I [use most] of the time, that’s the reason that I didn’t mention on 
that……… So, if there was like a medication that I used often that I’m used to it, then I was 
supposed to mention it on that [form].”[ID 5] 
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One participant also considered that they would be required to have a blood test to check 
illicit drug use or smoking before starting a clinical study, thus there was no need to be 
dishonest.  
 “I’ve seen them before in other questionnaires, so it’s something I won’t lie about. It’s 
something you do if somebody does, say, a blood test on you, they’ll see nicotine in your system. 
So, no issue with it really.” [ID 1] 
 
Unanimous agreement for researchers obtaining electronic medical history information  
 
When asked which clinic they attended if sick, most said they went to the community day 
hospital. A minority have medical aid, so may go to a private doctor, and all participants also 
go to a pharmacy or shop to buy over-the-counter medication for flu, colds or sinus, such as 
painkillers and vitamins for general health. Most participants reported, however, that they did 
not believe in traditional healers. 
 
 “I don’t talk to them because I’m not…it’s not that I don’t trust them, but I prefer going to 
the clinic” [ID 4]  
 
The only people who carry medical notes are those with chronic conditions, such as HIV and 
Crohn’s disease. One did not carry such a record, saying: 
 
 “INTERVIEWER: Medical records, do you keep a record, either your own or something the 
hospital or clinic or a doctor gave you, of your medical… 
 
INTERVIEWEE: No, I don’t have one at the moment, my doctor has one I’m sure, he always 
writes everything down.” [ID 6] 
 
None of the participants expressed any concern about us accessing their electronic records 
through the public health system. Some felt this would be the best option for obtaining the 
most comprehensive information on their health, as they did not remember everything that 
had happened in all clinic or hospital visits. Some doctors also did not provide them with all 
of the information. So, by accessing these medical records, researchers would get all the 
necessary data. 
 
 “No, I think you can have a look, but I mean I might not remember every visit, I don’t…there 
might be things doctors don’t always tell you exactly what they’re writing, so I don’t know, 
you can check.” [ID 6] 
 
 
4.2. Discussion 
 
Medical research is common in South Africa, so it is important to know what participants 
understand about taking part. In addition, it is essential to understand 
what influences potential participants’ reporting of their medical history, as sub-optimal 
reporting may affect whether people are eligible for a trial and the trial results. Healthy 
volunteer studies, in particular, rely on good medical history data. To the best of our 
knowledge, this study is the first in South Africa to investigate the situation of a healthy adult 
volunteer database, the information that applicants report when completing an online 
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questionnaire during recruitment, as compared to available medical records and a subsequent 
interview. 
 
The main findings of the study were: 1) We experienced a very low response rate to the 
advertisement for joining the healthy volunteer database, 2) people in this community are 
willing to consider taking part in clinical research, but have different understandings of what 
this means, 3) there were discrepancies between online self-reported health and medication 
data and what was found in a pilot database of electronic public health medical records, and a 
face-to-face interview, 4) the reasons for these differences, as perceived by the participants, 
included forgetting some information, feeling it was not relevant or important to report, or 
because of the attributes of the online questionnaire, and 5) these participants had no 
concerns about us accessing their electronic medical records. 
 
Efficient, cost-effective participant recruitment is widely recognized as a key determinant of 
success for clinical trials. Initially, we believed there would be a high response rate to our 
advertisements based on previous experience advertising for healthy participants in a malaria 
clinical trial, with advertisements placed in similar locations in the same hospital, as well as 
in print and online newspapers. In that case, hundreds of people responded within a very 
short time (personal communication: KI Barnes). While more research is needed to explore 
this, as the focus of the advertisements in these two scenarios was slightly different and 
because we did not explore this explicitly in our interviews, we propose that a key success 
factor was the inclusion of a phone number on the Barnes trial advertisements for people to 
send a “please call me” text to. Our findings suggest, therefore, that online recruitment on its 
own is not feasible for our context and investigators need to budget or staff and to factor in a 
reasonable time to call interested parties to elicit medical histories when planning their trials.  
 
A small number of participants attended the face-to-face interviews. The various reasons for 
this include the inability to contact them for interviews on the number or email address 
provided and often participants did not arrive for the appointment.  Among this small sample, 
the willingness of the public to join clinical trials seems reasonably accepted, although this 
does not indicate acceptance within the community. Ohmann et al. found that only 25% of 
225 visitors interviewed at a German university accepted taking part in clinical trials, with a 
likelihood of lower participation in surgical trials than in dental or pharmaceutical trials(75). 
Patients with cancer often participate to gain possible therapeutic benefits(76,77).   
 
The recruitment of participants is generally facilitated with financial reimbursement. In fact, a 
key reported motivation for participation is the financial reward(78,79). Kass et al. 
investigated study participation in the US and reported that for healthy volunteers, money 
was a motivating factor for 55% and the deciding factor for 46% many other motivations are 
described by healthy volunteers, such as contributing to science, helping others or personal 
benefits(36,80). In our study, the most frequently mentioned motivation was participants 
being content to help people through their contribution, even if they did not fully understand 
the meaning of being involved. Participants with chronic diseases, in particular, were eager to 
try a new medicine for their own benefit, while others were willing to be part of the research 
team. Both observations raise concerns, as it indicates a therapeutic misconception. However, 
while the people with chronic conditions, who considered themselves healthy, and therefore 
eligible, may not have been our target population for the volunteer database, they may be 
eligible for other studies. Similarly, while the high BMIs may exclude people from healthy 
volunteer studies, they may be suitable for studies with wider eligibility criteria, particularly 
where optimal dosing by weight is being investigated.  
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Understandably, people would consider taking an unpaid job as a trial participant or as part of 
the research team. As unemployment is very high in this community and unpaid positions are 
common, there is the hope that this may lead to paid employment as skills increase. However, 
it is critical to ensure that potential trial participants understand what taking part in a trial 
means, so that they may make an informed choice. Advertising for a volunteer database or 
specific trial, and completing an online health questionnaire, is the first step in a longer 
process of obtaining informed consent. Our study elicited useful suggestions from the Cape 
Town community for improving understanding of clinical trials, including a simply-worded 
social media page, and clear posters with pictures. We anticipated a low level of 
understanding of clinical research based on our previous experience of conducting trials in 
South Africa, yet our small sample showed diverse awareness, which may reflect what is also 
found in other settings. Despite what may be presumed about the relative ease of conducting 
trials in the US, where one would expect awareness of research to be higher, according to an 
article from Nature, nearly 20 percent of publicly-funded clinical trials there are delayed 
because they cannot register enough participants due to the general public’s lack of education 
on trials(81,82).  
 
In our small study, there were variations between self-reports of health and medicine use 
through the online questionnaire, the electronic medical records and the face-to-face 
interviews, which are similar in comparison to other reports. While not referring to a specific 
clinical trial, Eze-Nliam et al. reported that more than half of the discrepancies in their study 
were due to lack of self-reports by the participants(67). In contrast, another study aimed to 
compare the accuracy of online versus paper assessment methods to ascertain cigarette 
smoking status using a structured face-to-face interview as the gold standard. They found no 
statistically significant differences (83) . We cannot ascertain which method is more accurate 
than another because of our low sample size. However, were similar factors that influence 
medical history reports to another study conducted in Cape Town and Tanzania(4). These 
should be considered when trialists design ways of eliciting medical histories during 
recruitment. 
 
While electronic records will undoubtedly provide more information for clinical trial teams to 
accurately assess potential participants’ eligibility for trials, there were significant delays in 
obtaining the data from the Western Cape pilot data linkage project for this study. Thus, the 
feasibility of accessing data needs further exploration to ascertain if the problem was due to 
our study design, and a lack of understanding of this example of a clinical trial methodology 
research study, or to do with the ethics or practicalities of accessing such data, in general, for 
clinical trial purposes. Clinical trial methodology research is a new, but expanding, field. It 
aims to question the way clinical trials are designed, conducted, managed, analysed and 
reported. It is very important to understand some of these processes from the perspective of 
the trial participants, or potential participants, as it is for understanding patients’ experiences 
of healthcare in general. Hence, there has been a move towards patient and public 
involvement (PPI). The term "public" includes patients, applicants, caregivers and people 
who use health services and social care, and organizations representing people who use such 
services. Research that emphasises the public's needs and views is more likely to yield results 
that can be used to enhance health and social care. PPI in clinical research has greatly 
expanded and significant attention has recently been paid to understanding its impact on 
research. People take part in research for individual reasons, including a wish to improve 
their own or others’ treatment, and it could also be to have a 'voice’ (84).  
 
41 
 
It is significant, therefore, for both ethical and practical reasons, to involve the public in 
research. In addition to the benefits of contributing to the quality and relevance of research, 
broader democratic principles of citizenship also inform the underlying reason for involving 
members of the public in research. Ethically, PPI is encouraged on the basis that individuals 
who are affected by the state, or the community, in the case of a public health study, have the 
right to join in study decisions that may affect them. This includes the development of 
systems and processes to involve patients and the public in research; advising on the 
recruitment of patients as participants; engaging the public in the design and implementation 
of research; the dissemination and implementation of research findings once a study is 
completed(85).  
 
Reports of PPI outcomes are both positive and negative. Positive effects of PPI have 
influenced different studies, from the design of the study and the selection of outcomes to the 
distribution and implementation of results. Potential negative effects of PPI on studies have 
also informed, including "potential scientific and ethical conflicts in the design of protocols"; 
potential reductions in recruitment; prejudices in enrolment; power struggles between 
investigators and patients; untimely dissemination of study results prior to academic 
publication; and quality also reporting inconsistent across trials(86–88). Challenges have 
been raised with PPI, which indicates the need for a solid basis of evidence. For example, the 
research team perceives public contributors as having an excessively narrow or self-serving 
agenda or if they are not satisfactorily involved, in spite of the opportunity and support 
provided.  
 
PPI can work well if its objectives are pure, there are well-developed strategies for PPI in a 
study, and if PPI models are more responsive and managerial (e.g. membership in the trial 
management group), rather than limited to general supervision (e.g. membership in the trial 
management committee)(89). Our own study showed that potential trial participants were 
enthusiastic about giving us advice on how best to manage the recruitment to our adult 
volunteer database and were open to us accessing their electronic medical records. As the 
latter is only one part of a person’s medical experience, there may be other gaps in 
knowledge to be explored, such as how to obtain similar records from the myriad of private 
practitioners that people consult, and an accurate record of over-the-counter medication use. 
 
A limitation of this study was the low response rate to our advertisements and the significant 
delays in obtaining electronic medical records for people completing the online questionnaire. 
Ultimately,only eight medical records were obtained, which limited our ability to explore the 
differences in the responses to the questionnaire. Furthermore, this delay resulted in a short 
time in which to conduct face-to-face interviews, also resulting in a small sample size. 
Finally, the advertisements, online questionnaire, and interviews could only be conducted in 
English, which will have impacted the generalizability of our findings but may also have 
hampered the conversations within the interviews with people whose first language was not 
English.  
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4.3. Conclusion: 
Our study provides some evidence for places to advertise for an adult volunteer database, 
and optimal wording and format for an advert and an online questionnaire. We provided data 
to show  discrepancies between medical histories obtained through online self-reports 
questionnaire, electronic public sector medical records as well as face to face interview. More 
efforts are needed to help the general public understand the meaning of clinical trials. The 
main reasons for not reporting information in the questionnaires included forgetting, 
considering it not relevant/important, or because of the questionnaire attributes. We have 
shown that electronic medical records may be accessed to help understand potential 
participants’ eligibility for trials, but that the feasibility of accessing such data timeously may 
need further negotiation. 
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Investigator Signature Page 
I have read the protocol and agree that it contains all necessary details for carrying out the screening 
of applicants for inclusion in an adult volunteer database as described.  I will conduct this protocol as 
outlined therein and supervise staff that conduct the screening and maintain the database. 
I agree to inform all applicants that their involvement is not for any particular clinical trial and I will 
ensure that the requirements related to screening volunteers and obtaining informed consent are in 
accordance with ICH and South African Guidelines for Good Clinical Practice (GCP), including the 
Declaration of Helsinki (2008 and 2013) where applicable. 
I will not make any changes to the protocol without the Faculty of Health Sciences Human Research 
Ethics Committee’s (HREC) approval, except when necessary to minimise apparent immediate harm 
to volunteers. I agree to promptly report to the HREC any changes in the research activity and 
unanticipated problems involving risk to the participants in accordance with their standard operating 
procedures.   
I agree to maintain adequate and accurate records and make those records available in accordance 
with GCP and local requirements, where applicable. 
 
________________________________  Date: ________________________ 
Karen I Barnes 
Principal Investigator 
 
Division of Clinical Pharmacology 
Department of Medicine 
University of Cape Town (UCT) 
K45 Old Main Building 
Groote Schuur Hospital 
Observatory 7925 
South Africa 
 
Tel: +27 21 406 6294 / 4070 / 6996 
Fax: +27 21 650 3726 
Mobile: +27 82 440 2542 
Email: karen.barnes@uct.ac.za 
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Protocol Synopsis 
Protocol number AVDB01 
Protocol title Building and maintaining an adult volunteer database for future clinical trials 
Principal 
Investigator 
Professor Karen Barnes 
Division of Clinical Pharmacology 
University of Cape Town 
K45 Old Main Building 
Groote Schuur Hospital 
Observatory 7925, South Africa 
Tel: +27 21 406 6294 
Fax: +27 21 448 1989 
Email: karen.barnes@uct.ac.za 
Objective of 
screening 
To determine the eligibility of adult volunteers for future clinical trials to be 
conducted by the MCRG 
Eligibility criteria Inclusion Criteria 
• Written informed consent 
• Male and female, aged at least 18 years old 
• Body weight of at least 50 kg and a body mass index (BMI) within the 
range of 18-32 kg/m2 
• Good peripheral venous access 
• An ability to communicate well with the research staff, such that they 
are likely to understand and comply with future trial-specific 
requirements 
• Agrees to stay in contact with the MCRG for the foreseeable future, 
and no current plans to move away from the study area 
Exclusion Criteria 
• A history of hypersensitivity to any drugs 
• A history of anaphylaxis or severe allergic reaction 
• Resting vital signs (measured after 5 minutes in the supine position) 
outside of the following ranges: oral body temperature between 35.0 
and 37.5 °C, systolic blood pressure from 90 to 140 mm Hg, diastolic 
blood pressure from 50 to 90 mm Hg, pulse rate from 40 to 90 bpm 
• Orthostatic changes in blood pressure and heart rate measurements 
greater than: 20 mm Hg drop in systolic blood pressure, 10 mm Hg 
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drop in diastolic blood pressure, 20 bpm increase in heart rate 
[Orthostatic changes will be assessed by comparing supine 
measurements (after at least 5 minutes in the supine position) to 
measurements taken 3 minutes after standing up from the supine 
position] 
• A history of clinically significant ECG abnormalities, or any of the 
following ECG abnormalities at screening: PR >210 ms, QRS complex 
>120 ms, QTcF >450 ms or shortened QTcF less than 340 ms or a 
family history of long QT syndrome or sudden death, second or third 
degree atrioventricular block, incomplete, full or intermittent bundle 
branch block, abnormal T wave morphology, left ventricular 
hypertrophy with repolarisation abnormalities, right ventricular 
hypertrophy 
• A history of malignancy of any organ system (other than localised 
basal cell carcinoma of the skin), treated or untreated, within the past 
five years, regardless of whether there is evidence of local recurrence 
or metastases 
• Pregnant or lactating women 
• Fertile males and females, defined as physiologically capable of 
conceiving offspring, UNLESS agreeing to comply with two highly 
effective contraceptive methods during any subsequent clinical trial, 
including a follow-up period of possibly up to 12 weeks (e.g. oral 
contraceptives, injectable contraceptives, or intra-uterine device) 
• Use of tobacco products in the previous three months or a urine 
cotinine level ≥500 ng/ml, if conducted 
• Haemoglobin below 9.5 g/dl, if known 
• Clinically significant abnormalities on urine dipstick, if conducted 
• Recent (within the last three years) and/or recurrent history of 
autonomic dysfunction (e.g. recurrent episodes of fainting, 
palpitations, etc.) 
• Recent (within the last three years) and/or recurrent history of acute 
or chronic bronchospasm (including asthma and chronic obstructive 
pulmonary disease, treated or not treated) 
• A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody 
test result, if conducted 
• A history of endocrine disease, in particular, adrenal disorders such 
as Cushing's syndrome or Addison's disease, or diabetes mellitus (or 
a clinically abnormal fasting glucose) 
• A history of any food allergies 
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• Any surgical or medical condition which might significantly alter the 
absorption, distribution, metabolism, or excretion of drugs, or which 
may jeopardise the safety of the participant in likely future clinical 
trials.  The investigator should make this determination in 
consideration of the participant’s medical history and/or clinical or 
laboratory evidence, including any of the following:  Inflammatory 
bowel disease, ulcers, gastrointestinal or rectal bleeding in the last 
six months; major gastrointestinal tract surgery such as gastrectomy, 
gastroenterostomy, or bowel resection; or pancreatic injury or 
pancreatitis in the last six months. 
• Evidence of urinary obstruction or difficulty in voiding at screening 
• A history of drug or alcohol abuse within the 12 months prior to 
screening or a positive urine drug screen or breath alcohol result, if 
conducted 
• Any clinically significant mental disorder that could limit the validity 
of informed consent or the participant’s ability to comply with a 
future trial’s protocol requirements 
Identification and 
pre-selection 
Volunteers will be sourced from those who have been screened for (and/or 
enrolled in) our clinical trials and the general public. The former group will 
be asked at the time they finish participation in a clinical trial for consent to 
be included in the database. The latter group will be targeted through 
advertising and pre-screened by telephone. 
Screening process For those identified through pre-screening, each applicant will be asked for 
informed consent to join the database at a screening visit by a suitably 
qualified and trained member of staff. HIV tests will require separate 
written informed consent accompanied by adequate pre- and post-test 
counselling. HIV tests, however, will not be necessary for those who declare 
themselves to be HIV positive. 
 
Screening will involve the following assessments, the results of which are 
recorded in paper-based participant files. Only if applicants are eligible, will 
the results of these assessments be entered into the database. Should it be 
necessary, applicants will be invited back to discuss results of any tests and 
for referral to an appropriate practitioner: 
 
- Demographics, relevant medical and surgical history / current medical 
conditions, dietary allergies, intolerances and preferences, whether a blood 
donor. 
- Physical examination, vital signs, electrocardiogram (ECG), height and 
weight 
- Laboratory evaluations (should funds allow):  
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  - Blood (haemoglobin, fasting glucose, hepatitis B, HIV [not 
required for those declaring themselves to be HIV positive]);  
  - Urine: semi-quantitative urine dipstick analysis (specific 
gravity, pH, glucose, protein, bilirubin, ketones, leukocytes and blood); urine 
cotinine; a toxicology screen for drugs of abuse (amphetamines, 
barbiturates, benzodiazepines, cannabinoids, cocaine, and opiates); 
pregnancy (women only) 
 - Alcohol breath test  
Should a repeat value remain outside of the required range for eligibility, 
the applicant will be excluded from enrolment. 
Withdrawal from 
the database 
Volunteers may request to be removed from the database at any time for 
any reason. The database can also be terminated at any time for any reason 
by the Principal Investigator. Should this be done, all enrolled volunteers will 
be contacted to inform them of the decision as soon as possible. 
Safety of 
volunteers 
The Principal Investigator has a personal responsibility to closely monitor 
screened participants and take whatever measures necessary to ensure 
their safety. He/she also has the authority to terminate, suspend or require 
changes to the screening for safety concerns and may prohibit enrolment of 
a participant in the database if he/she has some suspicion that taking part in 
a subsequent clinical trial may place a volunteer at significant risk. 
 
Although enrolled volunteers are not yet part of a clinical trial, there may be 
some risk to them by being screened for, or included in, the database (e.g. 
bruising from blood tests). Although all reasonable efforts will be made to 
ensure confidentiality, there may be inadvertent problems relating to the 
loss of privacy. The research team managing the database will adhere to the 
FHS HREC policy: "Unanticipated Problems Involving Risks to Research 
Participants and Others Including Adverse Events".  
Data storage and 
management 
Source paper files will be kept in a secure location only accessible to the 
research team. Data management will be performed in accordance with 
regulatory requirements, including the Protection of Personal Information 
(POPI) Act (when implemented), and HREC requirements. Direct access to 
source data/documents will be allowed if required for subsequent trial-
related monitoring, audits, ethics committee reviews, and regulatory 
inspections, as is explicit in the informed consent. 
Ethical 
considerations 
There will be no payments of R50.00 made to those screened or enrolled. 
However, those attending a screening will be offered refreshments. Should 
applicants or enrolled participants be requested to come back to the unit for 
subsequent visits (e.g. for a repeat laboratory test or counselling), these will 
also be recompensed at R50.00 per visit to cover transport costs and 
inconvenience. 
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A description of the setup and maintenance of the database may be 
submitted for publication in due course; no information that could disclose 
the identity of any volunteer will be included in such a publication. 
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INTRODUCTION AND RATIONALE FOR THE ADULT VOLUNTEER DATABASE 
This protocol describes an adult volunteer database that will be built and maintained by UCT's Malaria 
Clinical Research Group (MCRG). The decision to develop this database was prompted by the MCRG’s 
experiences in screening participants for previous clinical trials. It was found that, for instance, 
approximately 400 people had to be pre-screened to screen 69, in order to ultimately enrol 26 healthy 
volunteers for a recent Phase 1 trial. Each stage of this process was lengthy and labour-intensive, 
possibly because the local population is not familiar with the concept of healthy volunteer studies and 
does not necessarily have a good knowledge of their health. For subsequent trials involving adult 
volunteers, it is critical that the process of screening is more efficient and cost-effective. By starting to 
build a database before our next trial is approved, our aim is to develop a strong pool of potential 
participants who can then be invited to trial-specific screening. However, the protocol is not intended to 
only include healthy adult volunteers as the group will likely conduct trials with other participant 
populations, for example, otherwise-healthy HIV positive participants to study antimalarial and 
antiretroviral drug interactions. 
This database could also potentially be shared with others in the Faculty of Health Sciences (FHS) once 
sufficient safeguards about data protection are in place. This could ultimately prevent duplication of 
efforts by different departments as regards advertising, recruitment, and screening of trial participants 
for what are possibly very similar protocols. Implementation of this standard process could facilitate the 
cost-effective conduct of clinical trials in the faculty while maintaining good quality processes and 
protection of the participants involved. However, the group will contact the HREC to discuss the plan 
should it decide to go this route. 
OBJECTIVE OF SCREENING FOR THE ADULT VOLUNTEER DATABASE 
The objective of this protocol is to determine the eligibility of adult volunteers for future clinical trials to 
be conducted by the MCRG.  
TARGET POPULATION 
The target population for the database is adult, male and female volunteers.  Eligibility will be based on 
the inclusion and exclusion criteria described below. 
Inclusion Criteria 
1. Written informed consent 
2. Male and female, aged at least 18 years old 
3. Body weight of at least 50 kg and a body mass index (BMI) within the range of 18-32 kg/m2 
4. Good peripheral venous access 
5. An ability to communicate well with the research staff, such that they are likely to understand and 
comply with future trial-specific requirements 
6. Agrees to stay in contact with the MCRG for the foreseeable future, and no current plans to move 
away from the study area 
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Exclusion Criteria 
1. A history of hypersensitivity to any drugs 
2. A history of anaphylaxis or severe allergic reaction 
3. Resting vital signs (measured after 5 minutes in the supine position) outside of the following 
ranges: oral body temperature between 35.0 and 37.5 °C, systolic blood pressure from 90 to 
140 mm Hg, diastolic blood pressure from 50 to 90 mm Hg, pulse rate from 40 to 90 bpm 
4. Orthostatic changes in blood pressure and heart rate measurements greater than: 20 mm Hg drop 
in systolic blood pressure, 10 mm Hg drop in diastolic blood pressure, 20 bpm increase in heart 
rate [Orthostatic changes will be assessed by comparing supine measurements (after at least 5 
minutes in the supine position) to measurements taken 3 minutes after standing up from the 
supine position] 
5. A history of clinically significant ECG abnormalities, or any of the following ECG abnormalities at 
screening: PR >210 ms, QRS complex >120 ms, QTcF >450 ms or shortened QTcF less than 340 ms 
or a family history of long QT syndrome or sudden death, second or third degree atrioventricular 
block, incomplete, full or intermittent bundle branch block, abnormal T wave morphology, left 
ventricular hypertrophy with repolarisation abnormalities, right ventricular hypertrophy 
6. A history of malignancy of any organ system (other than localised basal cell carcinoma of the skin), 
treated or untreated, within the past five years, regardless of whether there is evidence of local 
recurrence or metastases 
7. Pregnant or lactating women 
8. Fertile males and females, defined as physiologically capable of conceiving offspring, UNLESS 
agreeing to comply with two highly effective contraceptive methods during any subsequent 
clinical trial, including a follow-up period of possibly up to 12 weeks (e.g. oral contraceptives, 
injectable contraceptives, or intra-uterine device) 
9. Use of tobacco products in the previous three months or a urine cotinine level ≥500 ng/ml, if 
conducted 
10. Haemoglobin below 9.5 g/dl, if known (based on the lower limit of grade 1 anaemia in the US 
National Institute of Allergy and Infectious Diseases toxicity tables, although future studies in HIV-
negative healthy volunteers may require higher Hb levels) 
11. Clinically significant abnormalities on urine dipstick, if conducted 
12. Recent (within the last three years) and/or recurrent history of autonomic dysfunction (e.g. 
recurrent episodes of fainting, palpitations, etc.) 
13. Recent (within the last three years) and/or recurrent history of acute or chronic bronchospasm 
(including asthma and chronic obstructive pulmonary disease, treated or not treated) 
14. A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody test result, if conducted 
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15. A history of endocrine disease, in particular, adrenal disorders such as Cushing's syndrome or 
Addison's disease, or diabetes mellitus (or a clinically abnormal fasting glucose) 
16. A history of any food allergies 
17. Any surgical or medical condition which might significantly alter the absorption, distribution, 
metabolism, or excretion of drugs, or which may jeopardise the safety of the participant in likely 
future clinical trials.  The investigator should make this determination in consideration of the 
participant’s medical history and/or clinical or laboratory evidence, including any of the following: 
• Inflammatory bowel disease, ulcers, gastrointestinal or rectal bleeding in the last six months; 
• Major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel 
resection; or 
• Pancreatic injury or pancreatitis in the last six months. 
18. Evidence of urinary obstruction or difficulty in voiding at screening 
19. A history of drug or alcohol abuse within the 12 months prior to screening or a positive urine drug 
screen, or breath alcohol result, if conducted 
20. Any clinically significant mental disorder that could limit the validity of informed consent or the 
participant’s ability to comply with a future trial’s protocol requirements 
Justification of Inclusion and Exclusion Criteria 
The inclusion and exclusion criteria have been selected to minimise risk to the wellbeing of participants 
in likely future clinical trials while also allowing for various patient populations to be identified.  
 
HOW VOLUNTEERS WILL BE IDENTIFIED 
Volunteers for the database will be sourced from those who have been screened for (and/or enrolled in) 
our clinical trials and from the general public. Those from the former group who have been identified as 
fulfilling the database eligibility criteria will be asked at the time they finish participation in the clinical 
trial for consent to be included in the database. Those from the general public will be pre-selected and 
screened according to the process below: 
VOLUNTEER PRE-SELECTION PROCESS 
Advertising 
Adult volunteers will be recruited from within Cape Town and its surrounding areas. Advertising may be 
in print (e.g. newspapers, posters, leaflets, and website) and/or radio/television appearances. The text 
for printed adverts is given in Appendix 1, and the questions and answers presented in the information 
and consent document (Appendix 2) will be used on the website. Press releases/radio/television 
appearances will be discussed on an individual basis with the HREC.  
Pre-screening 
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A log of the name and contact details of any applicant will be maintained. A suitably trained member will 
contact each applicant and complete a brief pre-screening form (Appendix 3). Those who appear 
suitable for screening will be assigned the next available date/time for a visit to the Clinical Research 
Centre. He/she will be given directions and briefly advised what to expect in terms of the screening 
process. He/she will be requested to bring an ID document as this is critical to ensuring that those pre-
screened are the same as those subsequently screened, and ultimately enrolled, in the database and 
any subsequent clinical trial. Those who appear ineligible will be advised as such. 
VOLUNTEER SCREENING PROCESS 
On the day of screening, each applicant will be asked for informed consent to join the database 
(Appendix 2). The information will be given in written and verbal forms by a suitably qualified and 
trained member of staff and will be available in three local languages (English, Xhosa and Afrikaans).  
The information may be given to many applicants at the same time (e.g. with a PowerPoint 
presentation) but each applicant will have the opportunity to meet individually with staff to confirm 
consent. A simple comprehension test will be done by asking the applicant to explain certain parts of the 
database information as per the HREC’s guidelines.  
HIV tests will require separate written informed consent accompanied by adequate pre- and post-test 
counselling (Appendix 4). HIV tests, however, will not be necessary for those who declare themselves to 
be HIV positive. 
After informed consent, the screening visit will continue with the following assessments, the results of 
which are recorded in paper-based participant files. Only if applicants are eligible, will the results of 
these assessments be entered in the database. Should it be necessary, applicants will be invited back to 
discuss results of any tests and for referral to an appropriate practitioner. 
Demographics: Date of birth, age, gender and race/predominant ethnicity (recorded for the purposes of 
potential pharmacogenetic studies and to reflect the demographics of disease burden). 
Relevant medical and surgical history / current medical conditions: A detailed medical and surgical 
history and record of any medication taken for ≥ 4 weeks at any point in the last five years and any 
medication taken within the past six months. Medication includes over-the-counter, alternative and 
traditional medicines, as well as nutritional supplements and investigational products.  
Diet: Dietary allergies, intolerances, and preferences, including the use of grapefruit and caffeine. 
Blood donation: Whether a blood donor and, if so, the date of the last donation. 
Physical examination: General appearance, skin, neck (thyroid), ears, nose, throat, lungs, heart, 
abdomen, back, lymph nodes, extremities, vascular and neurological systems. If indicated as a result of 
the participant’s medical history, rectal, external genitalia, breast, and/or pelvic exams may be 
performed with the applicant’s verbal consent. 
Vital signs: Body temperature, heart rate and blood pressure assessments. Systolic and diastolic blood 
pressure will be measured with an appropriately sized cuff, after the applicant has been supine for at 
least five minutes.  Orthostatic changes to blood pressure and heart rate will also be assessed; he/she 
will be requested to stand after completion of the supine measurements, and blood pressure and heart 
rate will be recorded after three minutes in the standing position. 
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Electrocardiogram (ECG): Standard 12-lead ECGs.  Participants will rest in a supine position for at least 
ten minutes prior to the start of recording. Special attention will be given to changes in QT- and QRS-
intervals from baseline, T-wave morphology changes and dysrhythmias. 
Height and weight: Height in centimetres (cm) and body weight (to the nearest 0.1 kg in indoor clothing, 
but without shoes). 
Laboratory evaluations: Evaluations of limited laboratory parameters will be performed should funds 
allow. Results that fall outside of the specified eligibility criteria may be repeated once prior to 
enrolment in the database to exclude a possible laboratory error.  Should the repeat value remain 
outside of the required range for eligibility, the applicant will be excluded from enrolment in the 
database.  Laboratory results that fall outside of the normal reference range but are not considered 
clinically significant will be reviewed by the Principal Investigator who will confirm whether or not the 
participant is eligible for inclusion. Laboratory assessments (should funds allow) will include: 
• Blood: Haemoglobin, fasting glucose, hepatitis B, HIV (HIV testing is not required for 
those declaring themselves to be HIV positive). Appropriate pre- and post-test 
counselling will be part of the separate informed consent for HIV testing and HIV 
positivity will be confirmed by an ELISA.   
• Urine: A semi-quantitative urine dipstick analysis on a midstream urine sample to 
assess specific gravity, pH, glucose, protein, bilirubin, ketones, leukocytes and blood; 
urine cotinine levels; a toxicology screen for drugs of abuse (amphetamines, 
barbiturates, benzodiazepines, cannabinoids, cocaine, and opiates); pregnancy 
(women only). 
• Alcohol breath test  
VOLUNTEER IDENTIFICATION IN THE DATABASE 
During screening, applicants will be allocated a unique sequential screening number S00001, S00002. All 
eligible volunteers who agree to be enrolled in the database will then be allocated a unique sequential 
enrolment number. This will be three digits prefixed by the letters ‘AVDB’ (i.e. AVDB 001, AVDB 002, 
AVDB 003, etc. in ascending order) and will be the primary identifier to ensure consistency of reporting 
from the time of enrolment. 
WITHDRAWAL FROM OR CLOSURE OF THE DATABASE 
Enrolled volunteers may request to be removed from the database at any time for any reason. The 
database can also be terminated at any time for any reason by the Principal Investigator. Should this be 
done, all enrolled volunteers will be contacted to inform them of the decision as soon as possible.  
ENSURING THE SAFETY OF DATABASE PARTICIPANTS 
The Principal Investigator has a personal responsibility to closely monitor screened participants and take 
whatever measures necessary to ensure their safety. He/she also has the authority to terminate, 
suspend or require changes to the screening for safety concerns and may prohibit enrolment of a 
participant in the database if he/she has some suspicion that taking part in a subsequent clinical trial 
may place a volunteer at significant risk. 
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Although enrolled volunteers are not yet part of a clinical trial, there may be some risk to them by being 
screened for, or included in, the database (e.g. in terms of bruising from blood tests). In addition, 
although all reasonable efforts will be made to ensure confidentiality, there may be inadvertent 
problems relating to the loss of privacy. Therefore, the research team managing the database will 
adhere to the FHS HREC policy: "Unanticipated Problems Involving Risks to Research Participants and 
Others Including Adverse Events".  
DATA STORAGE AND DATABASE MANAGEMENT 
Source documents (paper files) will be kept in a secure location only accessible to the research team. 
These will consist of notes containing demographic and medical information, laboratory results, ECG 
traces, and reports.  
The database itself will only include information about volunteers who are enrolled. A designated data 
manager will review the data entered for completeness, and request the research team make any 
required corrections or additions. Data management will be performed in accordance with regulatory 
requirements, including the Protection of Personal Information (POPI) Act (when it is implemented), and 
the HREC requirements for the "Collection and Storage of Data or Biological Specimens for Research 
Purposes" and/or "Databases, registries and repositories" (where relevant). The Principal Investigator 
will, however, provide direct access to source data/documents if required for subsequent trial-related 
monitoring, audits, ethics committee reviews, and regulatory inspections. This will be made explicit in 
the informed consent documents. 
ETHICAL CONSIDERATIONS 
Regulatory and Ethical Compliance 
The development of an adult volunteer database will be conducted, where relevant, according to the 
ethical principles set forth in the Declaration of Helsinki 2008 and 2013, ICH-GCP, South African Good 
Clinical Practice Guidelines, and other local regulatory requirements (including those relating to data 
protection as mentioned above). 
Compensation 
There will be no payments of R50.00 made to those screened or enrolled in the database to cover their 
travel expenses. However, those attending a screening visit will be offered refreshments. Should 
applicants or enrolled participants be requested to come back to the unit for subsequent visits, these 
will be recompensed at R50.00 per visit to cover transport costs. Trial-related screening visits will be 
recompensed according to each trial’s approved rate. 
Publications 
A description of the setup and maintenance of the database may be submitted for publication in due 
course; no information that could disclose the identity of any volunteer will be included in such a 
publication. 
RESEARCH TEAM 
The Principal Investigator will ensure that the research team is suitably qualified and/or experienced in 
order to play their role, as detailed in their CV, training records and a delegation of tasks document kept 
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on file by the MCRG. Screening and database processes will also be described in standard operating 
procedures in which the team will be trained and there will be periodic oversight of the process by a 
senior member of the team. 
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VOLUNTEER INFORMATION LEAFLET & CONSENT FORM 
 
DATE OF FIRST INFORMED CONSENT DISCUSSION:   /   /      
        (dd/mm/yyyy) 
RESEARCH INSTITUTION:  
Clinical Research Unit, J51 (J floor) Old Main Building, Groote Schuur Hospital, Observatory, South Africa. 
Tel: 021 406 6294/ 4070/ 6996 Fax: 021 650 3726 
Database team member conducting informed consent interview: ___________________________ 
Introduction 
You are invited to join our clinical research volunteer database. Before you agree to join, you need to 
understand why we have a database and what will happen.  Please read this leaflet carefully and ask us 
if anything is not clear or if you need more information. Please don’t agree to take part until you are 
happy that you understand what will happen, and any possible risks (dangers). 
Why do we have a volunteer database? 
Before a new medicine is allowed to be given to patients, it has to be tested to see if it is safe and works 
properly, and what the best dose would be. The medicines are tested in clinical research studies. We 
have a volunteer database, where we type some of your details into a computer so that we can keep 
records of people who have said that they would like to be part of future clinical research studies. 
What are clinical research studies (also called clinical trials)?  
These are experiments where we find out about new treatments for various illnesses. Volunteers come 
into a research centre and take the new treatment for a short time while being closely looked after by 
doctors and nurses. A number of tests are done in these studies to see how their bodies react to the 
new treatment.  
Do I have to have an illness to take part?  
No, not always. In fact, many studies are done with completely healthy volunteers. As they are not ill, 
the new medicine is not going to treat any illness. Therefore these volunteers will not get any medical 
help from the medicine. Instead, they help others by helping us develop new medicines. Sometimes we 
ask people with some illnesses to take a new treatment that is not for their illness but for something 
else. These volunteers will also not get any medical help from the medicine. 
Why would I want to join the volunteer database?  
It is because of volunteers that we are able to make new medicines for those who need them. You may 
not be helped by the medicine if you are not ill. Once the medicine is found to be safe, people with the 
illness take it to see if it helps them. 
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What happens if I want to part of the volunteer database? 
• To join our volunteer database you need to visit us for 3-4 hours. We will explain what is going to
happen and then you will have a physical examination by qualified medical staff. You will also
answer questions, including about your health and what medicines you normally take.
• We may then take a blood or urine sample for some tests (to check if is safe for you to consider
taking part in future clinical research studies) and, if so, may ask you back for another visit to give
you the results or do a repeat test, for which we will give you R50.00 to cover any transport costs.
These tests could include checking the level of your blood or sugar and if you are infected with
HIV, hepatitis B or C. You will need to sign a separate informed consent form for us if we test you
for HIV. You may decline the HIV test, but this will mean you will not be able to participate in some
studies. If you already know you are HIV positive, then you do not need to do another test.
• If you are a woman, we may check if you are pregnant as it would not be safe for you or your baby
to be in our clinical research studies.
• You may be asked to give a urine sample so that we can make sure you are not using any drugs
that can be abused (cocaine, amphetamine, opioids, dagga, benzodiazepines and barbiturates)
and will also test for any abnormalities in your urine by dipping a plastic strip into the urine
sample.
• We may also do an alcohol breath test and/or a urine test to check if you smoke.
• We will also measure if you have any heart problems by doing an electrocardiogram (ECG). This is
done by putting stickers on your chest to which wires will be attached to measure how your heart
beats for a minute or two. You will have to remove the clothes from your chest and lie still for a
few minutes during the test. It is not painful but may be uncomfortable.
• If you agree to join the database and we think it is safe for you to take part in future clinical
research studies, we will keep your details safe in our files.
• If our tests show that you have some problem we will, with your permission, refer you to an
appropriate healthcare facility.
• It is very important for us to make sure that it is safe for you to join a study in the future. So we
ask that you please tell us everything about your health, medicines and habits (e.g. smoking).
• If you have a regular doctor that you visit, please provide us with his or her contact details. With
your permission, we would like to contact him or her to make sure that you do not have any illness
that may affect your safety in our future clinical research studies.
• We also need to know that we can contact you if we need to so please keep us informed if you
change contact details or decide to move away from Cape Town.
66 
Will my personal details be kept private? 
Your records will be seen by some of the research staff, and by authorized persons, such as from the 
University Ethics Committee, who checks to see that the database is being carried out correctly. If you 
give permission to be part of the database we will type your records into the computer and they may 
also be seen by staff from future clinical research studies. However, we will ask for your permission for 
that at the time of the future study. All those people have to keep your details confidential. Your identity 
will also not be given in any publication.  
What happens if I want to join a research study? 
If we have a research study for you in the future, we will ask you to come back in to us for another visit. 
We will explain what the new study is and what will happen, how long the study will take, how many 
times you need to come in, if you need to stay overnight in our ward and what tests you will have. You 
may also have to stop using certain foods and drinks while you are in some studies. We will also tell you 
what we know about the medicine and what the risks (possible dangers) are for you. 
What are the risks (possible dangers) of being in the database or a future research study? 
For the database, there may be small problems, such as bruising from the blood tests you may have. 
For future research studies, we have to follow strict rules and there are also people who look at our 
plans and decide whether they are safe enough. Before you join a research study in the future we will 
explain what we know about the medicine so you can choose whether to take part. The medicine you 
take in these studies may not help you if you do not have the illness the new medicine is for. There may, 
however, be some risks because we don't know enough about the medicines yet.  
Will I be paid to take part? 
You will not be paid to take part in the database. However, you will be offered refreshments and a sum 
of R50.00 to compensate for travel expenses. Should you be asked to come back to the unit for 
subsequent visits, you will be paid R50 per visit to cover transport costs.  
What if I don't want to be a volunteer? 
You can decide not to join our volunteer database or to be taken out of the database or any research 
study at any time and for any reason. You can also go home and think about joining and talk to others 
like your family. We can also stop the database if we decide to - if we do this, we will let you know. 
What if I have any questions? 
If you have any questions or wish to report any problems you have experienced related to the study, 
please contact the lead investigator, Dr Phumla Sinxadi (phumla.sinxadi@uct.ac.za or at 021 650 4096) 
or the study principal investigator, Prof Karen Barnes (karen.barnes@uct.ac.za at 021 406 6294). If you 
have any concerns regarding your rights and welfare as they relate to this study you can contact the 
University of Cape Town Human Research Ethics Committee Chairperson, Professor Marc Blockman 
(Room E52-24 Old Main Building, Groote Schuur Hospital, Observatory, 7925,  +2721 406 6338). 
Signature page 
Protocol no: MCRG AVDB01 
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Protocol title: Building and maintaining an adult volunteer database for future clinical trials 
I have received a copy of this information leaflet and consent form about the volunteer database. 
The database has been fully explained to me and I have been given the opportunity to ask any questions 
or discuss joining with others like my family. I know that I am free to leave the database at any time for 
any reason. I know that my personal records will be looked at by the database staff, and authorized 
persons who check to see that the database is being carried out correctly. However, my records will not 
be shown to anyone else without my permission and my name will not appear in any report. I agree to 
be part of the database. I understand that I have not given permission to be in any clinical research 
study as this will be discussed with me if a suitable study comes along. 
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Print volunteer’s  name: 
___________________ 
Home address: 
___________________ 
Work Address: 
___________________ 
Signature:  ___________________  Date:  __________________
Print witness’s name: 
(if volunteer gives oral, not signed 
consent) 
__________________  
Signature: 
__________________ 
Date: 
__________________ 
Print  presenter’s name: 
(who presented/explained the 
 document) 
__________________ 
Signature: 
__________________ 
Date: 
__________________ 
Print Investigator’s name: 
__________________ 
Signature: 
__________________ 
Date: 
___________________ 
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Appendix 2: Advertisement 
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Appendix 3: Online pre-screen checklist adapted from existing adult volunteer database 
protocol. 
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Appendix 4: In-depth interview 
Participant ID: 
Facilitator’s initials: 
Co-facilitator’s initials:  
Date (dd/mm/yy): 
Warm up 
Tell me a bit about yourself; where do you live, how long have you lived in this community, do you work?  
Part I - Health status and treatments taken prior to the interview  
Introductory  
How did you come to hear about this database?     
What did you understand the advert to be for?  
What do you understand about the database? What is it about? Tell me what you think clinical studies/trials are about. 
What do you think your role is in this research?     
Which clinics do you normally attend? /Do you ever see any other doctors/other healthcare workers? 
Wait for full response and take notes of any relevant illness/treatments mentioned 
Medical/drug history  
How is your health at the moment?  
When did you last see a doctor? (Probes: what was that for? What did he/she recommend? Mention clinics, doctors reported 
above) 
Are you taking, or have you taken, any medicines in the past month? (Probes: when did you start? Have you had them before?) 
What are you taking these for? (Probes: when did that start? Have you had this before?) 
Have you had any times in your life when you were quite ill? (Probes: when was that? What treatment did you have for that? 
When was the last time you experienced that? What treatment did you receive?) 
What other illnesses did you have as a child? (Probes: when was that? What treatment did you have for that?) 
And as an adult? (Probes: when was that? What treatment did you have for that?) 
Have you taken/used anything [else] for any other reason?  For example, anything to prevent ill health / just for general good 
health/contraception/vitamins, traditional/alternative medicines. 
Who do you normally see for your health issues? (Probes: some people [also] speak to their family/friends/a pharmacist 
/shopkeeper/a sangoma/alternative health practitioner)  
When was the last time you spoke to any of these people about your health (go through each)? (Probes: what brought you to see 
that person? What did they recommend?) 
Do you have any medication at home from any past visits to a hospital, general practitioner or day clinic? Probe if yes 
Do you have a medical record, follow up card or hospital card? Probe, if yes. 
Part II - Reasons for differences in reporting depending on the method and help in accessing all information (probe all 
references to health/treatments)  
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Thank you so much for completing the online questionnaire. So, let’s look together at what you said in that (and also what your 
medical records contain) and what we have discussed today. I’d really like your help finding the best way for us to collect this 
information.  
It does not matter if we find there is a difference between what you said in the questionnaire and (what is in the medical records 
or) with what we have discussed today – there is no right or wrong and you will not be in any trouble either way.  
Browse different data sources together, if discrepancy: 
Why do you think we didn’t get [information in medical records and/or interview] at the time you completed the questionnaire? 
(Probes: did we ask the right questions? What are the right questions?  
What helps you remember some things better than others? 
Were there any things on the questionnaire you weren’t sure about? 
What makes you feel that you needed to/didn’t need to mention x?  
For each answer try to probe further e.g. if he/she says something was not important to report ask why, and which things are 
important to report/which are not)  
If no access to electronic records: 
If not addressed already: What helps you remember some things better than others? 
Were there any questions on the online questionnaire you weren’t sure about? 
How do you feel about us accessing your medical records from hospitals, clinics, doctors? How should we go about finding those 
records? (Probes, public, private, pharmacies) 
Would we find anything different to what you have mentioned about your health today and in the questions you completed on the 
computer for us with those records? Why is that? 
If we want to get the most information on the health and treatments of people who want to take part in databases like this, how 
would you suggest we do this? (Probes: diaries, pictures of medicines, who should ask them the questions (doctor, nurse, 
community health worker, traditional healer), what type of questions)  
Can you recommend ideas for us for where we can find other people to consider joining the volunteer database for future clinical 
trials? (Posters, leaflets – where? Newspapers, online?) 
What wording do you think we should use to invite those people? 
What do people need to know about clinical trials? 
Discuss any misunderstanding about the intention of the database, particularly as regards clinical trials. 
Closing 
We are now coming to the end of our talk. Is there anything else anyone would like to add about the discussion, your health, 
treatments and how we can get the most accurate information in our databases?  
Summarise 
Thank participant 
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Appendix 5: Informed consent 
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Appendix 6: Ethics approval 
signature removed to avoid exposure online
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signature removed
76 
77 
signature removed to avoid exposure online
78 
signature removed 
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80 
signature removed 
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